市場調査レポート

商品コード

胃がんの世界市場規模・シェア・産業動向分析レポート：投与経路別（注射・経口）、治療タイプ別、疾患タイプ別、流通チャネル別、薬剤クラス別、地域別展望・予測、2023～2029年

Global Gastric Cancer Market Size, Share & Industry Trends Analysis Report By Route of Administration (Injectable and Oral), By Treatment Type, By Disease Type, By Distribution Channel, By Drug Class, By Regional Outlook and Forecast, 2023 - 2029

出版日: 2023年04月28日 | 発行: KBV Research

| ページ情報: 英文 326 Pages | 納期: 即納可能

価格

PDF (Single User License)

USD 3,600 564,876円

レポートPDFを1名のみがご利用頂けるライセンスです。PDF内のテキスト等のコピー＆ペーストは可能です。PDFの印刷も可能です。印刷したもののご利用はPDFのライセンス保持者に限定されます。

PDF (Site License)

USD 4,320 677,851円

レポートPDFを同一企業内の5名までご利用頂けるライセンスです。PDF内のテキスト等のコピー＆ペーストは可能です。PDFの印刷も可能です。印刷したもののご利用はPDFのご利用範囲に準拠します。

PDF (Enterprisewide License)

USD 6,048 948,991円

レポートPDFを同一企業のすべての方に使用頂けるライセンスです。PDF内のテキスト等のコピーは可能です。PDFの印刷回数に制限はありません。印刷したもののご利用はPDFのご利用範囲に準拠します。

価格表記: USDを日本円(税抜)に換算

本日の銀行送金レート: 1USD=156.91円

全表示
概要
図表
目次

概要

サンプル依頼リストに入れる

胃がん市場規模は、2029年には69億米ドルに達し、予測期間中にCAGR17.6%で成長すると予測されています。

胃の中の異なる部位に、異なるタイミングでがんが発生するため、症状や予後もさまざまになります。治療法の選択は、がんの発生部位によって異なる場合があります。例えば、胃食道接合部に発生する、あるいは胃食道接合部から始まる悪性腫瘍は、食道腫瘍と同様の病期分類や治療を行うことが多いです。胃の最も内側の粘膜には、これらの悪性腫瘍を発生させる腺細胞があります。

胃腺がんは、腸型とびまん型の2つが基本形です。がん細胞に特定の遺伝子変化がある可能性が高いため、標的薬治療ができる可能性が高くなります。びまん型は一般的に、より急速に広がります。腸型に比べると頻度は低く、治療が困難な場合が多いです。

COVID-19影響度分析

診断と治療の遅れは、COVID-19パンデミックによる胃がんへの主な影響です。がんの診断と治療が遅れた結果、患者の転帰に大きく影響することがあります。がん調査、特に胃がんの新規治療法を検討する臨床試験も、パンデミックによって妨げられました。COVID-19の制限により、数多くの臨床試験が延期または中断され、病気の新しい治療法の創出を遅らせている可能性があります。しかし、パンデミック期間中も重症例は治療されていました。これらの要素を考慮すると、胃がん市場はCOVID-19による影響が中程度であったことがわかります。

市場成長要因

標的療法や免疫療法の受け入れ拡大、新薬の導入

疾患の分子基盤の理解が深まったことにより、市場に開発・導入される標的治療薬や免疫治療薬の数が増加しています。2010年以降、ハーセプチンなどの抗HER-2薬が販売されるようになりました。現在、胃がんの治療法としてEGFRやPD-1の標的療法と免疫療法が生み出されています。さらに、臨床パイプラインにある医薬品の承認とその後の発売が胃がん市場の成長を後押しすると予想されています。

胃がんの有病率の上昇

胃がんは、東アジアで最も有病率の高いがんの種類です。2020年には、新たに110万人の胃がん患者が発生し、77万人の胃がん関連死が予測され、男性の罹患率は女性の2倍であることが多いです。予測期間中、胃がんの有病率の上昇により、胃がん治療薬の需要が増加し、胃がん治療薬の市場動向として注目されると予測されます。予測期間中、これは胃がん市場の成長を助けると予想されます。

市場抑制要因

限られた治療オプションとそれらに関連する副作用の組み合わせ

化学療法、放射線療法、またはその2つの組み合わせと手術を使ってがんを治療することは可能です。化学療法で使用される薬剤は、急速に分裂するがん細胞を攻撃することで機能しますが、健康な細胞も傷つける可能性があり、吐き気、嘔吐、疲労感などの不快な副作用が生じます。今後数年間は、この点が市場需要の障壁となることが予想されます。また、治療費の高騰や胃がん治療薬の入手が比較的限られているなどの要因が、予測期間を通じて胃がん市場の成長を阻害すると予測されています。

疾患タイプ別展望

胃がん市場は、疾患タイプ別に、腺がん、リンパ腫、消化管間質腫瘍、カルチノイド腫瘍、その他に分類されます。2022年の胃がん市場では、リンパ腫のセグメントがかなりの収益シェアを占めています。免疫系のリンパ球は、そもそもこれらの腫瘍が発生する場所です。胃壁で始まるリンパ腫もありますが、ほとんどのリンパ腫は体の他の部位で始まります。リンパ腫の種類や他の変数に応じて、これらの腫瘍は治療することができ、良好な予後を持つことができます。リンパ腫に対する認識の高まりは、このセグメントの拡大を後押しすると予測されます。

治療タイプの展望

治療タイプ別に見ると、胃がん市場は、免疫療法、標的療法、化学療法、放射線療法・外科療法に分類されます。2022年の胃がん市場では、標的療法分野がかなりの収益シェアを獲得しています。標的療法では、がん患者は、がん細胞が持つ遺伝子やタンパク質を特異的に標的とする医薬品を持つことで治療を受けます。がんの標的療法には、ホルモン治療薬、遺伝子発現制御薬、血管新生阻害薬、アポトーシス誘導薬、シグナル伝達阻害薬など、さまざまな形態があります。

薬物クラスの展望

薬剤クラス別では、胃がん市場はPD-1/PD-L1阻害薬、抗HER-2薬、VEGFR2阻害薬、その他に分けられます。2022年には、PD-1/PD-L1阻害薬セグメントが胃がん市場を独占し、最大の収益シェアを獲得しました。プログラム細胞死タンパク質1（PD-1）やPD-L1などの免疫チェックポイントタンパク質は、健康な組織に害を及ぼす可能性のある過剰な免疫反応を防止するのに役立つことが多いです。重症または転移性胃がんの治療には、ニボルマブ、ペムブロリズマブ、アテゾリズマブなど、多くのPD-1/PD-L1阻害薬が認可されています。進行胃がん患者では、いくつかの薬剤が生存期間の延長や腫瘍の成長を遅らせる効果を示しています。

投与経路の展望

投与経路に基づき、胃がん市場は経口剤と注射剤に区分されます。2022年、胃がん市場では注射剤が最大の収益シェアを記録しました。注射剤は血流に直接投与されるため、経口剤よりも早く吸収される可能性があります。これは、迅速な対応が必要とされる進行性または転移性の胃がんの患者に役立ちます。また、静脈内投与では、より多くの薬剤が標的部位に到達するため、バイオアベイラビリティが向上します。これにより、副作用が軽減され、治療結果が向上する可能性があります。

販売チャネルの展望

胃がん市場は、流通チャネル別に、専門店・小売薬局、病院薬局、その他に分類されます。病院薬局セグメントは、2022年の胃がん市場における顕著な収益シェアを占めると予測されています。政府が支援する病院薬局の設立や有利な償還が、病院薬局セグメントの成長の主な原因となっています。これらの理由に加えて、政府が提供するがん治療への強力なサポートがあります。また、患者数の増加、胃がんの有病率の増加、がん治療施設の増加により、この分野は拡大すると予測されています。

地域別展望

地域別に見ると、胃がん市場は北米、欧州、アジア太平洋、LAMEA(ラテンアメリカ・中東・アフリカ)で分析されています。2022年には、アジア太平洋地域が最大の収益シェアを獲得し、胃がん市場を牽引しました。市場の拡大は、アジア太平洋地域における老年人口の増加によってもたらされています。胃がん診断の需要は、消化器系腫瘍やリンパ腫の流行によってもたらされています。さらに、アジア太平洋地域では胃がん患者が増加しており、予測される期間中にアジア太平洋地域の市場成長を促進すると予想されています。

市場参入企業がとる主な戦略は、パートナーシップです。カーディナルマトリックスに掲載された分析によると、胃がん市場ではPfizer, Inc.が主要な先駆者です。Merck &Co., Inc.、Teva Pharmaceutical Industries Ltd.、Eli Lilly and Companyなどは、胃がん市場における主要な革新企業のひとつです。

市場の定義
目的
市場範囲
セグメンテーション
- 世界の胃がん市場：投与経路別
- 世界の胃がん市場：治療タイプ別
- 世界の胃がん市場：疾患タイプ別
- 世界の胃がん市場：流通チャネル別
- 世界の胃がん市場：薬剤クラス別
- 世界の胃がん市場：地域別
調査手法

第2章市場概要

イントロダクション
- 概要
  - 市場構成とシナリオ
市場に影響を与える主な要因
- 市場促進要因
- 市場抑制要因

第3章競合分析- 世界

KBVカーディナルマトリックス
最近の業界全体の戦略的展開
- パートナーシップ、コラボレーション、および契約
- 製品の発売と製品の拡大
- 承認とトライアル
主要成功戦略
- 主要なリーディングストラテジー

第4章世界の胃がん市場：投与経路別

世界の注射剤市場：地域別
世界の経口市場：地域別

第5章世界の胃がん市場：治療タイプ別

世界の化学療法市場：地域別
世界の標的療法市場：地域別
世界の免疫療法市場：地域別
世界の放射線治療および手術市場：地域別

第6章世界の胃がん市場：疾患タイプ別

世界の腺がん市場：地域別
世界のカルチノイド腫瘍市場：地域別
世界の消化管間質腫瘍市場：地域別
世界のリンパ腫市場：地域別
世界のその他の市場：地域別

第7章世界の胃がん市場：流通チャネル別

世界の専門薬局および小売薬局市場：地域別
世界の病院薬局市場：地域別
世界のその他の市場：地域別

第8章世界の胃がん市場：薬剤クラス別

世界のPD-1/PD-L1阻害薬市場：地域別
世界の抗HER-2薬市場：地域別
世界のVEGFR2阻害薬市場：地域別
世界のその他の市場：地域別

第9章世界の胃がん市場：地域別

北米
- 北米の市場：国別
  - 米国
  - カナダ
  - メキシコ
  - その他北米地域
欧州
- 欧州の市場：国別
  - ドイツ
  - 英国
  - フランス
  - ロシア
  - スペイン
  - イタリア
  - その他欧州地域
アジア太平洋
- アジア太平洋の市場：国別
  - 中国
  - 日本
  - インド
  - 韓国
  - シンガポール
  - マレーシア
  - その他アジア太平洋地域
LAMEA（ラテンアメリカ・中東・アフリカ）
- LAMEAの市場：国別
  - ブラジル
  - アルゼンチン
  - アラブ首長国連邦
  - サウジアラビア
  - 南アフリカ
  - ナイジェリア
  - LAMEAのその他地域

第10章企業プロファイル

Novartis AG
Pfizer, Inc
Viatris, Inc（Mylan N.V.）
F Hoffmann-La Roche Ltd.
Eli Lilly And Company
Merck & Co, Inc.
Teva Pharmaceutical Industries Ltd
Bristol Myers Squibb Company
Celltrion Healthcare Co, Ltd.
Samsung Biologics Co, Ltd.（Samsung Bioepis Co., Ltd.）

図表

LIST OF TABLES

TABLE 1 Global Gastric Cancer Market, 2019 - 2022, USD Million
TABLE 2 Global Gastric Cancer Market, 2023 - 2029, USD Million
TABLE 3 Partnerships, Collaborations and Agreements- Gastric Cancer Market
TABLE 4 Product Launches And Product Expansions- Gastric Cancer Market
TABLE 5 Approvals & Trials - Gastric Cancer Market
TABLE 6 Global Gastric Cancer Market by Route of Administration, 2019 - 2022, USD Million
TABLE 7 Global Gastric Cancer Market by Route of Administration, 2023 - 2029, USD Million
TABLE 8 Global Injectable Market by Region, 2019 - 2022, USD Million
TABLE 9 Global Injectable Market by Region, 2023 - 2029, USD Million
TABLE 10 Global Oral Market by Region, 2019 - 2022, USD Million
TABLE 11 Global Oral Market by Region, 2023 - 2029, USD Million
TABLE 12 Global Gastric Cancer Market by Treatment Type, 2019 - 2022, USD Million
TABLE 13 Global Gastric Cancer Market by Treatment Type, 2023 - 2029, USD Million
TABLE 14 Global Chemotherapy Market by Region, 2019 - 2022, USD Million
TABLE 15 Global Chemotherapy Market by Region, 2023 - 2029, USD Million
TABLE 16 Global Targeted Therapy Market by Region, 2019 - 2022, USD Million
TABLE 17 Global Targeted Therapy Market by Region, 2023 - 2029, USD Million
TABLE 18 Global Immunotherapy Market by Region, 2019 - 2022, USD Million
TABLE 19 Global Immunotherapy Market by Region, 2023 - 2029, USD Million
TABLE 20 Global Radiation Therapy & Surgery Market by Region, 2019 - 2022, USD Million
TABLE 21 Global Radiation Therapy & Surgery Market by Region, 2023 - 2029, USD Million
TABLE 22 Global Gastric Cancer Market by Disease Type, 2019 - 2022, USD Million
TABLE 23 Global Gastric Cancer Market by Disease Type, 2023 - 2029, USD Million
TABLE 24 Global Adenocarcinoma Market by Region, 2019 - 2022, USD Million
TABLE 25 Global Adenocarcinoma Market by Region, 2023 - 2029, USD Million
TABLE 26 Global Carcinoid Tumor Market by Region, 2019 - 2022, USD Million
TABLE 27 Global Carcinoid Tumor Market by Region, 2023 - 2029, USD Million
TABLE 28 Global Gastrointestinal Stromal Tumor Market by Region, 2019 - 2022, USD Million
TABLE 29 Global Gastrointestinal Stromal Tumor Market by Region, 2023 - 2029, USD Million
TABLE 30 Global Lymphoma Market by Region, 2019 - 2022, USD Million
TABLE 31 Global Lymphoma Market by Region, 2023 - 2029, USD Million
TABLE 32 Global Others Market by Region, 2019 - 2022, USD Million
TABLE 33 Global Others Market by Region, 2023 - 2029, USD Million
TABLE 34 Global Gastric Cancer Market by Distribution Channel, 2019 - 2022, USD Million
TABLE 35 Global Gastric Cancer Market by Distribution Channel, 2023 - 2029, USD Million
TABLE 36 Global Specialty & Retail Pharmacies Market by Region, 2019 - 2022, USD Million
TABLE 37 Global Specialty & Retail Pharmacies Market by Region, 2023 - 2029, USD Million
TABLE 38 Global Hospital Pharmacies Market by Region, 2019 - 2022, USD Million
TABLE 39 Global Hospital Pharmacies Market by Region, 2023 - 2029, USD Million
TABLE 40 Global Others Market by Region, 2019 - 2022, USD Million
TABLE 41 Global Others Market by Region, 2023 - 2029, USD Million
TABLE 42 Global Gastric Cancer Market by Drug Class, 2019 - 2022, USD Million
TABLE 43 Global Gastric Cancer Market by Drug Class, 2023 - 2029, USD Million
TABLE 44 Global PD-1/PD-L1 Inhibitors Market by Region, 2019 - 2022, USD Million
TABLE 45 Global PD-1/PD-L1 Inhibitors Market by Region, 2023 - 2029, USD Million
TABLE 46 Global HER2 Antagonists Market by Region, 2019 - 2022, USD Million
TABLE 47 Global HER2 Antagonists Market by Region, 2023 - 2029, USD Million
TABLE 48 Global VEGFR2 Antagonists Market by Region, 2019 - 2022, USD Million
TABLE 49 Global VEGFR2 Antagonists Market by Region, 2023 - 2029, USD Million
TABLE 50 Global Others Market by Region, 2019 - 2022, USD Million
TABLE 51 Global Others Market by Region, 2023 - 2029, USD Million
TABLE 52 Global Gastric Cancer Market by Region, 2019 - 2022, USD Million
TABLE 53 Global Gastric Cancer Market by Region, 2023 - 2029, USD Million
TABLE 54 North America Gastric Cancer Market, 2019 - 2022, USD Million
TABLE 55 North America Gastric Cancer Market, 2023 - 2029, USD Million
TABLE 56 North America Gastric Cancer Market by Route of Administration, 2019 - 2022, USD Million
TABLE 57 North America Gastric Cancer Market by Route of Administration, 2023 - 2029, USD Million
TABLE 58 North America Injectable Market by Country, 2019 - 2022, USD Million
TABLE 59 North America Injectable Market by Country, 2023 - 2029, USD Million
TABLE 60 North America Oral Market by Country, 2019 - 2022, USD Million
TABLE 61 North America Oral Market by Country, 2023 - 2029, USD Million
TABLE 62 North America Gastric Cancer Market by Treatment Type, 2019 - 2022, USD Million
TABLE 63 North America Gastric Cancer Market by Treatment Type, 2023 - 2029, USD Million
TABLE 64 North America Chemotherapy Market by Country, 2019 - 2022, USD Million
TABLE 65 North America Chemotherapy Market by Country, 2023 - 2029, USD Million
TABLE 66 North America Targeted Therapy Market by Country, 2019 - 2022, USD Million
TABLE 67 North America Targeted Therapy Market by Country, 2023 - 2029, USD Million
TABLE 68 North America Immunotherapy Market by Country, 2019 - 2022, USD Million
TABLE 69 North America Immunotherapy Market by Country, 2023 - 2029, USD Million
TABLE 70 North America Radiation Therapy & Surgery Market by Country, 2019 - 2022, USD Million
TABLE 71 North America Radiation Therapy & Surgery Market by Country, 2023 - 2029, USD Million
TABLE 72 North America Gastric Cancer Market by Disease Type, 2019 - 2022, USD Million
TABLE 73 North America Gastric Cancer Market by Disease Type, 2023 - 2029, USD Million
TABLE 74 North America Adenocarcinoma Market by Country, 2019 - 2022, USD Million
TABLE 75 North America Adenocarcinoma Market by Country, 2023 - 2029, USD Million
TABLE 76 North America Carcinoid Tumor Market by Country, 2019 - 2022, USD Million
TABLE 77 North America Carcinoid Tumor Market by Country, 2023 - 2029, USD Million
TABLE 78 North America Gastrointestinal Stromal Tumor Market by Country, 2019 - 2022, USD Million
TABLE 79 North America Gastrointestinal Stromal Tumor Market by Country, 2023 - 2029, USD Million
TABLE 80 North America Lymphoma Market by Country, 2019 - 2022, USD Million
TABLE 81 North America Lymphoma Market by Country, 2023 - 2029, USD Million
TABLE 82 North America Others Market by Country, 2019 - 2022, USD Million
TABLE 83 North America Others Market by Country, 2023 - 2029, USD Million
TABLE 84 North America Gastric Cancer Market by Distribution Channel, 2019 - 2022, USD Million
TABLE 85 North America Gastric Cancer Market by Distribution Channel, 2023 - 2029, USD Million
TABLE 86 North America Specialty & Retail Pharmacies Market by Country, 2019 - 2022, USD Million
TABLE 87 North America Specialty & Retail Pharmacies Market by Country, 2023 - 2029, USD Million
TABLE 88 North America Hospital Pharmacies Market by Country, 2019 - 2022, USD Million
TABLE 89 North America Hospital Pharmacies Market by Country, 2023 - 2029, USD Million
TABLE 90 North America Others Market by Country, 2019 - 2022, USD Million
TABLE 91 North America Others Market by Country, 2023 - 2029, USD Million
TABLE 92 North America Gastric Cancer Market by Drug Class, 2019 - 2022, USD Million
TABLE 93 North America Gastric Cancer Market by Drug Class, 2023 - 2029, USD Million
TABLE 94 North America PD-1/PD-L1 Inhibitors Market by Country, 2019 - 2022, USD Million
TABLE 95 North America PD-1/PD-L1 Inhibitors Market by Country, 2023 - 2029, USD Million
TABLE 96 North America HER2 Antagonists Market by Country, 2019 - 2022, USD Million
TABLE 97 North America HER2 Antagonists Market by Country, 2023 - 2029, USD Million
TABLE 98 North America VEGFR2 Antagonists Market by Country, 2019 - 2022, USD Million
TABLE 99 North America VEGFR2 Antagonists Market by Country, 2023 - 2029, USD Million
TABLE 100 North America Others Market by Country, 2019 - 2022, USD Million
TABLE 101 North America Others Market by Country, 2023 - 2029, USD Million
TABLE 102 North America Gastric Cancer Market by Country, 2019 - 2022, USD Million
TABLE 103 North America Gastric Cancer Market by Country, 2023 - 2029, USD Million
TABLE 104 US Gastric Cancer Market, 2019 - 2022, USD Million
TABLE 105 US Gastric Cancer Market, 2023 - 2029, USD Million
TABLE 106 US Gastric Cancer Market by Route of Administration, 2019 - 2022, USD Million
TABLE 107 US Gastric Cancer Market by Route of Administration, 2023 - 2029, USD Million
TABLE 108 US Gastric Cancer Market by Treatment Type, 2019 - 2022, USD Million
TABLE 109 US Gastric Cancer Market by Treatment Type, 2023 - 2029, USD Million
TABLE 110 US Gastric Cancer Market by Disease Type, 2019 - 2022, USD Million
TABLE 111 US Gastric Cancer Market by Disease Type, 2023 - 2029, USD Million
TABLE 112 US Gastric Cancer Market by Distribution Channel, 2019 - 2022, USD Million
TABLE 113 US Gastric Cancer Market by Distribution Channel, 2023 - 2029, USD Million
TABLE 114 US Gastric Cancer Market by Drug Class, 2019 - 2022, USD Million
TABLE 115 US Gastric Cancer Market by Drug Class, 2023 - 2029, USD Million
TABLE 116 Canada Gastric Cancer Market, 2019 - 2022, USD Million
TABLE 117 Canada Gastric Cancer Market, 2023 - 2029, USD Million
TABLE 118 Canada Gastric Cancer Market by Route of Administration, 2019 - 2022, USD Million
TABLE 119 Canada Gastric Cancer Market by Route of Administration, 2023 - 2029, USD Million
TABLE 120 Canada Gastric Cancer Market by Treatment Type, 2019 - 2022, USD Million
TABLE 121 Canada Gastric Cancer Market by Treatment Type, 2023 - 2029, USD Million
TABLE 122 Canada Gastric Cancer Market by Disease Type, 2019 - 2022, USD Million
TABLE 123 Canada Gastric Cancer Market by Disease Type, 2023 - 2029, USD Million
TABLE 124 Canada Gastric Cancer Market by Distribution Channel, 2019 - 2022, USD Million
TABLE 125 Canada Gastric Cancer Market by Distribution Channel, 2023 - 2029, USD Million
TABLE 126 Canada Gastric Cancer Market by Drug Class, 2019 - 2022, USD Million
TABLE 127 Canada Gastric Cancer Market by Drug Class, 2023 - 2029, USD Million
TABLE 128 Mexico Gastric Cancer Market, 2019 - 2022, USD Million
TABLE 129 Mexico Gastric Cancer Market, 2023 - 2029, USD Million
TABLE 130 Mexico Gastric Cancer Market by Route of Administration, 2019 - 2022, USD Million
TABLE 131 Mexico Gastric Cancer Market by Route of Administration, 2023 - 2029, USD Million
TABLE 132 Mexico Gastric Cancer Market by Treatment Type, 2019 - 2022, USD Million
TABLE 133 Mexico Gastric Cancer Market by Treatment Type, 2023 - 2029, USD Million
TABLE 134 Mexico Gastric Cancer Market by Disease Type, 2019 - 2022, USD Million
TABLE 135 Mexico Gastric Cancer Market by Disease Type, 2023 - 2029, USD Million
TABLE 136 Mexico Gastric Cancer Market by Distribution Channel, 2019 - 2022, USD Million
TABLE 137 Mexico Gastric Cancer Market by Distribution Channel, 2023 - 2029, USD Million
TABLE 138 Mexico Gastric Cancer Market by Drug Class, 2019 - 2022, USD Million
TABLE 139 Mexico Gastric Cancer Market by Drug Class, 2023 - 2029, USD Million
TABLE 140 Rest of North America Gastric Cancer Market, 2019 - 2022, USD Million
TABLE 141 Rest of North America Gastric Cancer Market, 2023 - 2029, USD Million
TABLE 142 Rest of North America Gastric Cancer Market by Route of Administration, 2019 - 2022, USD Million
TABLE 143 Rest of North America Gastric Cancer Market by Route of Administration, 2023 - 2029, USD Million
TABLE 144 Rest of North America Gastric Cancer Market by Treatment Type, 2019 - 2022, USD Million
TABLE 145 Rest of North America Gastric Cancer Market by Treatment Type, 2023 - 2029, USD Million
TABLE 146 Rest of North America Gastric Cancer Market by Disease Type, 2019 - 2022, USD Million
TABLE 147 Rest of North America Gastric Cancer Market by Disease Type, 2023 - 2029, USD Million
TABLE 148 Rest of North America Gastric Cancer Market by Distribution Channel, 2019 - 2022, USD Million
TABLE 149 Rest of North America Gastric Cancer Market by Distribution Channel, 2023 - 2029, USD Million
TABLE 150 Rest of North America Gastric Cancer Market by Drug Class, 2019 - 2022, USD Million
TABLE 151 Rest of North America Gastric Cancer Market by Drug Class, 2023 - 2029, USD Million
TABLE 152 Europe Gastric Cancer Market, 2019 - 2022, USD Million
TABLE 153 Europe Gastric Cancer Market, 2023 - 2029, USD Million
TABLE 154 Europe Gastric Cancer Market by Route of Administration, 2019 - 2022, USD Million
TABLE 155 Europe Gastric Cancer Market by Route of Administration, 2023 - 2029, USD Million
TABLE 156 Europe Injectable Market by Country, 2019 - 2022, USD Million
TABLE 157 Europe Injectable Market by Country, 2023 - 2029, USD Million
TABLE 158 Europe Oral Market by Country, 2019 - 2022, USD Million
TABLE 159 Europe Oral Market by Country, 2023 - 2029, USD Million
TABLE 160 Europe Gastric Cancer Market by Treatment Type, 2019 - 2022, USD Million
TABLE 161 Europe Gastric Cancer Market by Treatment Type, 2023 - 2029, USD Million
TABLE 162 Europe Chemotherapy Market by Country, 2019 - 2022, USD Million
TABLE 163 Europe Chemotherapy Market by Country, 2023 - 2029, USD Million
TABLE 164 Europe Targeted Therapy Market by Country, 2019 - 2022, USD Million
TABLE 165 Europe Targeted Therapy Market by Country, 2023 - 2029, USD Million
TABLE 166 Europe Immunotherapy Market by Country, 2019 - 2022, USD Million
TABLE 167 Europe Immunotherapy Market by Country, 2023 - 2029, USD Million
TABLE 168 Europe Radiation Therapy & Surgery Market by Country, 2019 - 2022, USD Million
TABLE 169 Europe Radiation Therapy & Surgery Market by Country, 2023 - 2029, USD Million
TABLE 170 Europe Gastric Cancer Market by Disease Type, 2019 - 2022, USD Million
TABLE 171 Europe Gastric Cancer Market by Disease Type, 2023 - 2029, USD Million
TABLE 172 Europe Adenocarcinoma Market by Country, 2019 - 2022, USD Million
TABLE 173 Europe Adenocarcinoma Market by Country, 2023 - 2029, USD Million
TABLE 174 Europe Carcinoid Tumor Market by Country, 2019 - 2022, USD Million
TABLE 175 Europe Carcinoid Tumor Market by Country, 2023 - 2029, USD Million
TABLE 176 Europe Gastrointestinal Stromal Tumor Market by Country, 2019 - 2022, USD Million
TABLE 177 Europe Gastrointestinal Stromal Tumor Market by Country, 2023 - 2029, USD Million
TABLE 178 Europe Lymphoma Market by Country, 2019 - 2022, USD Million
TABLE 179 Europe Lymphoma Market by Country, 2023 - 2029, USD Million
TABLE 180 Europe Others Market by Country, 2019 - 2022, USD Million
TABLE 181 Europe Others Market by Country, 2023 - 2029, USD Million
TABLE 182 Europe Gastric Cancer Market by Distribution Channel, 2019 - 2022, USD Million
TABLE 183 Europe Gastric Cancer Market by Distribution Channel, 2023 - 2029, USD Million
TABLE 184 Europe Specialty & Retail Pharmacies Market by Country, 2019 - 2022, USD Million
TABLE 185 Europe Specialty & Retail Pharmacies Market by Country, 2023 - 2029, USD Million
TABLE 186 Europe Hospital Pharmacies Market by Country, 2019 - 2022, USD Million
TABLE 187 Europe Hospital Pharmacies Market by Country, 2023 - 2029, USD Million
TABLE 188 Europe Others Market by Country, 2019 - 2022, USD Million
TABLE 189 Europe Others Market by Country, 2023 - 2029, USD Million
TABLE 190 Europe Gastric Cancer Market by Drug Class, 2019 - 2022, USD Million
TABLE 191 Europe Gastric Cancer Market by Drug Class, 2023 - 2029, USD Million
TABLE 192 Europe PD-1/PD-L1 Inhibitors Market by Country, 2019 - 2022, USD Million
TABLE 193 Europe PD-1/PD-L1 Inhibitors Market by Country, 2023 - 2029, USD Million
TABLE 194 Europe HER2 Antagonists Market by Country, 2019 - 2022, USD Million
TABLE 195 Europe HER2 Antagonists Market by Country, 2023 - 2029, USD Million
TABLE 196 Europe VEGFR2 Antagonists Market by Country, 2019 - 2022, USD Million
TABLE 197 Europe VEGFR2 Antagonists Market by Country, 2023 - 2029, USD Million
TABLE 198 Europe Others Market by Country, 2019 - 2022, USD Million
TABLE 199 Europe Others Market by Country, 2023 - 2029, USD Million
TABLE 200 Europe Gastric Cancer Market by Country, 2019 - 2022, USD Million
TABLE 201 Europe Gastric Cancer Market by Country, 2023 - 2029, USD Million
TABLE 202 Germany Gastric Cancer Market, 2019 - 2022, USD Million
TABLE 203 Germany Gastric Cancer Market, 2023 - 2029, USD Million
TABLE 204 Germany Gastric Cancer Market by Route of Administration, 2019 - 2022, USD Million
TABLE 205 Germany Gastric Cancer Market by Route of Administration, 2023 - 2029, USD Million
TABLE 206 Germany Gastric Cancer Market by Treatment Type, 2019 - 2022, USD Million
TABLE 207 Germany Gastric Cancer Market by Treatment Type, 2023 - 2029, USD Million
TABLE 208 Germany Gastric Cancer Market by Disease Type, 2019 - 2022, USD Million
TABLE 209 Germany Gastric Cancer Market by Disease Type, 2023 - 2029, USD Million
TABLE 210 Germany Gastric Cancer Market by Distribution Channel, 2019 - 2022, USD Million
TABLE 211 Germany Gastric Cancer Market by Distribution Channel, 2023 - 2029, USD Million
TABLE 212 Germany Gastric Cancer Market by Drug Class, 2019 - 2022, USD Million
TABLE 213 Germany Gastric Cancer Market by Drug Class, 2023 - 2029, USD Million
TABLE 214 UK Gastric Cancer Market, 2019 - 2022, USD Million
TABLE 215 UK Gastric Cancer Market, 2023 - 2029, USD Million
TABLE 216 UK Gastric Cancer Market by Route of Administration, 2019 - 2022, USD Million
TABLE 217 UK Gastric Cancer Market by Route of Administration, 2023 - 2029, USD Million
TABLE 218 UK Gastric Cancer Market by Treatment Type, 2019 - 2022, USD Million
TABLE 219 UK Gastric Cancer Market by Treatment Type, 2023 - 2029, USD Million
TABLE 220 UK Gastric Cancer Market by Disease Type, 2019 - 2022, USD Million
TABLE 221 UK Gastric Cancer Market by Disease Type, 2023 - 2029, USD Million
TABLE 222 UK Gastric Cancer Market by Distribution Channel, 2019 - 2022, USD Million
TABLE 223 UK Gastric Cancer Market by Distribution Channel, 2023 - 2029, USD Million
TABLE 224 UK Gastric Cancer Market by Drug Class, 2019 - 2022, USD Million
TABLE 225 UK Gastric Cancer Market by Drug Class, 2023 - 2029, USD Million
TABLE 226 France Gastric Cancer Market, 2019 - 2022, USD Million
TABLE 227 France Gastric Cancer Market, 2023 - 2029, USD Million
TABLE 228 France Gastric Cancer Market by Route of Administration, 2019 - 2022, USD Million
TABLE 229 France Gastric Cancer Market by Route of Administration, 2023 - 2029, USD Million
TABLE 230 France Gastric Cancer Market by Treatment Type, 2019 - 2022, USD Million
TABLE 231 France Gastric Cancer Market by Treatment Type, 2023 - 2029, USD Million
TABLE 232 France Gastric Cancer Market by Disease Type, 2019 - 2022, USD Million
TABLE 233 France Gastric Cancer Market by Disease Type, 2023 - 2029, USD Million
TABLE 234 France Gastric Cancer Market by Distribution Channel, 2019 - 2022, USD Million
TABLE 235 France Gastric Cancer Market by Distribution Channel, 2023 - 2029, USD Million
TABLE 236 France Gastric Cancer Market by Drug Class, 2019 - 2022, USD Million
TABLE 237 France Gastric Cancer Market by Drug Class, 2023 - 2029, USD Million
TABLE 238 Russia Gastric Cancer Market, 2019 - 2022, USD Million
TABLE 239 Russia Gastric Cancer Market, 2023 - 2029, USD Million
TABLE 240 Russia Gastric Cancer Market by Route of Administration, 2019 - 2022, USD Million
TABLE 241 Russia Gastric Cancer Market by Route of Administration, 2023 - 2029, USD Million
TABLE 242 Russia Gastric Cancer Market by Treatment Type, 2019 - 2022, USD Million
TABLE 243 Russia Gastric Cancer Market by Treatment Type, 2023 - 2029, USD Million
TABLE 244 Russia Gastric Cancer Market by Disease Type, 2019 - 2022, USD Million
TABLE 245 Russia Gastric Cancer Market by Disease Type, 2023 - 2029, USD Million
TABLE 246 Russia Gastric Cancer Market by Distribution Channel, 2019 - 2022, USD Million
TABLE 247 Russia Gastric Cancer Market by Distribution Channel, 2023 - 2029, USD Million
TABLE 248 Russia Gastric Cancer Market by Drug Class, 2019 - 2022, USD Million
TABLE 249 Russia Gastric Cancer Market by Drug Class, 2023 - 2029, USD Million
TABLE 250 Spain Gastric Cancer Market, 2019 - 2022, USD Million
TABLE 251 Spain Gastric Cancer Market, 2023 - 2029, USD Million
TABLE 252 Spain Gastric Cancer Market by Route of Administration, 2019 - 2022, USD Million
TABLE 253 Spain Gastric Cancer Market by Route of Administration, 2023 - 2029, USD Million
TABLE 254 Spain Gastric Cancer Market by Treatment Type, 2019 - 2022, USD Million
TABLE 255 Spain Gastric Cancer Market by Treatment Type, 2023 - 2029, USD Million
TABLE 256 Spain Gastric Cancer Market by Disease Type, 2019 - 2022, USD Million
TABLE 257 Spain Gastric Cancer Market by Disease Type, 2023 - 2029, USD Million
TABLE 258 Spain Gastric Cancer Market by Distribution Channel, 2019 - 2022, USD Million
TABLE 259 Spain Gastric Cancer Market by Distribution Channel, 2023 - 2029, USD Million
TABLE 260 Spain Gastric Cancer Market by Drug Class, 2019 - 2022, USD Million
TABLE 261 Spain Gastric Cancer Market by Drug Class, 2023 - 2029, USD Million
TABLE 262 Italy Gastric Cancer Market, 2019 - 2022, USD Million
TABLE 263 Italy Gastric Cancer Market, 2023 - 2029, USD Million
TABLE 264 Italy Gastric Cancer Market by Route of Administration, 2019 - 2022, USD Million
TABLE 265 Italy Gastric Cancer Market by Route of Administration, 2023 - 2029, USD Million
TABLE 266 Italy Gastric Cancer Market by Treatment Type, 2019 - 2022, USD Million
TABLE 267 Italy Gastric Cancer Market by Treatment Type, 2023 - 2029, USD Million
TABLE 268 Italy Gastric Cancer Market by Disease Type, 2019 - 2022, USD Million
TABLE 269 Italy Gastric Cancer Market by Disease Type, 2023 - 2029, USD Million
TABLE 270 Italy Gastric Cancer Market by Distribution Channel, 2019 - 2022, USD Million
TABLE 271 Italy Gastric Cancer Market by Distribution Channel, 2023 - 2029, USD Million
TABLE 272 Italy Gastric Cancer Market by Drug Class, 2019 - 2022, USD Million
TABLE 273 Italy Gastric Cancer Market by Drug Class, 2023 - 2029, USD Million
TABLE 274 Rest of Europe Gastric Cancer Market, 2019 - 2022, USD Million
TABLE 275 Rest of Europe Gastric Cancer Market, 2023 - 2029, USD Million
TABLE 276 Rest of Europe Gastric Cancer Market by Route of Administration, 2019 - 2022, USD Million
TABLE 277 Rest of Europe Gastric Cancer Market by Route of Administration, 2023 - 2029, USD Million
TABLE 278 Rest of Europe Gastric Cancer Market by Treatment Type, 2019 - 2022, USD Million
TABLE 279 Rest of Europe Gastric Cancer Market by Treatment Type, 2023 - 2029, USD Million
TABLE 280 Rest of Europe Gastric Cancer Market by Disease Type, 2019 - 2022, USD Million
TABLE 281 Rest of Europe Gastric Cancer Market by Disease Type, 2023 - 2029, USD Million
TABLE 282 Rest of Europe Gastric Cancer Market by Distribution Channel, 2019 - 2022, USD Million
TABLE 283 Rest of Europe Gastric Cancer Market by Distribution Channel, 2023 - 2029, USD Million
TABLE 284 Rest of Europe Gastric Cancer Market by Drug Class, 2019 - 2022, USD Million
TABLE 285 Rest of Europe Gastric Cancer Market by Drug Class, 2023 - 2029, USD Million

TABLE 286 Asia Pacific Gastric Cancer Market, 2019 - 2022, USD Million
TABLE 287 Asia Pacific Gastric Cancer Market, 2023 - 2029, USD Million
TABLE 288 Asia Pacific Gastric Cancer Market by Route of Administration, 2019 - 2022, USD Million
TABLE 289 Asia Pacific Gastric Cancer Market by Route of Administration, 2023 - 2029, USD Million
TABLE 290 Asia Pacific Injectable Market by Country, 2019 - 2022, USD Million
TABLE 291 Asia Pacific Injectable Market by Country, 2023 - 2029, USD Million
TABLE 292 Asia Pacific Oral Market by Country, 2019 - 2022, USD Million
TABLE 293 Asia Pacific Oral Market by Country, 2023 - 2029, USD Million
TABLE 294 Asia Pacific Gastric Cancer Market by Treatment Type, 2019 - 2022, USD Million
TABLE 295 Asia Pacific Gastric Cancer Market by Treatment Type, 2023 - 2029, USD Million
TABLE 296 Asia Pacific Chemotherapy Market by Country, 2019 - 2022, USD Million
TABLE 297 Asia Pacific Chemotherapy Market by Country, 2023 - 2029, USD Million
TABLE 298 Asia Pacific Targeted Therapy Market by Country, 2019 - 2022, USD Million
TABLE 299 Asia Pacific Targeted Therapy Market by Country, 2023 - 2029, USD Million
TABLE 300 Asia Pacific Immunotherapy Market by Country, 2019 - 2022, USD Million
TABLE 301 Asia Pacific Immunotherapy Market by Country, 2023 - 2029, USD Million
TABLE 302 Asia Pacific Radiation Therapy & Surgery Market by Country, 2019 - 2022, USD Million
TABLE 303 Asia Pacific Radiation Therapy & Surgery Market by Country, 2023 - 2029, USD Million
TABLE 304 Asia Pacific Gastric Cancer Market by Disease Type, 2019 - 2022, USD Million
TABLE 305 Asia Pacific Gastric Cancer Market by Disease Type, 2023 - 2029, USD Million
TABLE 306 Asia Pacific Adenocarcinoma Market by Country, 2019 - 2022, USD Million
TABLE 307 Asia Pacific Adenocarcinoma Market by Country, 2023 - 2029, USD Million
TABLE 308 Asia Pacific Carcinoid Tumor Market by Country, 2019 - 2022, USD Million
TABLE 309 Asia Pacific Carcinoid Tumor Market by Country, 2023 - 2029, USD Million
TABLE 310 Asia Pacific Gastrointestinal Stromal Tumor Market by Country, 2019 - 2022, USD Million
TABLE 311 Asia Pacific Gastrointestinal Stromal Tumor Market by Country, 2023 - 2029, USD Million
TABLE 312 Asia Pacific Lymphoma Market by Country, 2019 - 2022, USD Million
TABLE 313 Asia Pacific Lymphoma Market by Country, 2023 - 2029, USD Million
TABLE 314 Asia Pacific Others Market by Country, 2019 - 2022, USD Million
TABLE 315 Asia Pacific Others Market by Country, 2023 - 2029, USD Million
TABLE 316 Asia Pacific Gastric Cancer Market by Distribution Channel, 2019 - 2022, USD Million
TABLE 317 Asia Pacific Gastric Cancer Market by Distribution Channel, 2023 - 2029, USD Million
TABLE 318 Asia Pacific Specialty & Retail Pharmacies Market by Country, 2019 - 2022, USD Million
TABLE 319 Asia Pacific Specialty & Retail Pharmacies Market by Country, 2023 - 2029, USD Million
TABLE 320 Asia Pacific Hospital Pharmacies Market by Country, 2019 - 2022, USD Million
TABLE 321 Asia Pacific Hospital Pharmacies Market by Country, 2023 - 2029, USD Million
TABLE 322 Asia Pacific Others Market by Country, 2019 - 2022, USD Million
TABLE 323 Asia Pacific Others Market by Country, 2023 - 2029, USD Million
TABLE 324 Asia Pacific Gastric Cancer Market by Drug Class, 2019 - 2022, USD Million
TABLE 325 Asia Pacific Gastric Cancer Market by Drug Class, 2023 - 2029, USD Million
TABLE 326 Asia Pacific PD-1/PD-L1 Inhibitors Market by Country, 2019 - 2022, USD Million
TABLE 327 Asia Pacific PD-1/PD-L1 Inhibitors Market by Country, 2023 - 2029, USD Million
TABLE 328 Asia Pacific HER2 Antagonists Market by Country, 2019 - 2022, USD Million
TABLE 329 Asia Pacific HER2 Antagonists Market by Country, 2023 - 2029, USD Million
TABLE 330 Asia Pacific VEGFR2 Antagonists Market by Country, 2019 - 2022, USD Million
TABLE 331 Asia Pacific VEGFR2 Antagonists Market by Country, 2023 - 2029, USD Million
TABLE 332 Asia Pacific Others Market by Country, 2019 - 2022, USD Million
TABLE 333 Asia Pacific Others Market by Country, 2023 - 2029, USD Million
TABLE 334 Asia Pacific Gastric Cancer Market by Country, 2019 - 2022, USD Million
TABLE 335 Asia Pacific Gastric Cancer Market by Country, 2023 - 2029, USD Million
TABLE 336 China Gastric Cancer Market, 2019 - 2022, USD Million
TABLE 337 China Gastric Cancer Market, 2023 - 2029, USD Million
TABLE 338 China Gastric Cancer Market by Route of Administration, 2019 - 2022, USD Million
TABLE 339 China Gastric Cancer Market by Route of Administration, 2023 - 2029, USD Million
TABLE 340 China Gastric Cancer Market by Treatment Type, 2019 - 2022, USD Million
TABLE 341 China Gastric Cancer Market by Treatment Type, 2023 - 2029, USD Million
TABLE 342 China Gastric Cancer Market by Disease Type, 2019 - 2022, USD Million
TABLE 343 China Gastric Cancer Market by Disease Type, 2023 - 2029, USD Million
TABLE 344 China Gastric Cancer Market by Distribution Channel, 2019 - 2022, USD Million
TABLE 345 China Gastric Cancer Market by Distribution Channel, 2023 - 2029, USD Million
TABLE 346 China Gastric Cancer Market by Drug Class, 2019 - 2022, USD Million
TABLE 347 China Gastric Cancer Market by Drug Class, 2023 - 2029, USD Million
TABLE 348 Japan Gastric Cancer Market, 2019 - 2022, USD Million
TABLE 349 Japan Gastric Cancer Market, 2023 - 2029, USD Million
TABLE 350 Japan Gastric Cancer Market by Route of Administration, 2019 - 2022, USD Million
TABLE 351 Japan Gastric Cancer Market by Route of Administration, 2023 - 2029, USD Million
TABLE 352 Japan Gastric Cancer Market by Treatment Type, 2019 - 2022, USD Million
TABLE 353 Japan Gastric Cancer Market by Treatment Type, 2023 - 2029, USD Million
TABLE 354 Japan Gastric Cancer Market by Disease Type, 2019 - 2022, USD Million
TABLE 355 Japan Gastric Cancer Market by Disease Type, 2023 - 2029, USD Million
TABLE 356 Japan Gastric Cancer Market by Distribution Channel, 2019 - 2022, USD Million
TABLE 357 Japan Gastric Cancer Market by Distribution Channel, 2023 - 2029, USD Million
TABLE 358 Japan Gastric Cancer Market by Drug Class, 2019 - 2022, USD Million
TABLE 359 Japan Gastric Cancer Market by Drug Class, 2023 - 2029, USD Million
TABLE 360 India Gastric Cancer Market, 2019 - 2022, USD Million
TABLE 361 India Gastric Cancer Market, 2023 - 2029, USD Million
TABLE 362 India Gastric Cancer Market by Route of Administration, 2019 - 2022, USD Million
TABLE 363 India Gastric Cancer Market by Route of Administration, 2023 - 2029, USD Million
TABLE 364 India Gastric Cancer Market by Treatment Type, 2019 - 2022, USD Million
TABLE 365 India Gastric Cancer Market by Treatment Type, 2023 - 2029, USD Million
TABLE 366 India Gastric Cancer Market by Disease Type, 2019 - 2022, USD Million
TABLE 367 India Gastric Cancer Market by Disease Type, 2023 - 2029, USD Million
TABLE 368 India Gastric Cancer Market by Distribution Channel, 2019 - 2022, USD Million
TABLE 369 India Gastric Cancer Market by Distribution Channel, 2023 - 2029, USD Million
TABLE 370 India Gastric Cancer Market by Drug Class, 2019 - 2022, USD Million
TABLE 371 India Gastric Cancer Market by Drug Class, 2023 - 2029, USD Million
TABLE 372 South Korea Gastric Cancer Market, 2019 - 2022, USD Million
TABLE 373 South Korea Gastric Cancer Market, 2023 - 2029, USD Million
TABLE 374 South Korea Gastric Cancer Market by Route of Administration, 2019 - 2022, USD Million
TABLE 375 South Korea Gastric Cancer Market by Route of Administration, 2023 - 2029, USD Million
TABLE 376 South Korea Gastric Cancer Market by Treatment Type, 2019 - 2022, USD Million
TABLE 377 South Korea Gastric Cancer Market by Treatment Type, 2023 - 2029, USD Million
TABLE 378 South Korea Gastric Cancer Market by Disease Type, 2019 - 2022, USD Million
TABLE 379 South Korea Gastric Cancer Market by Disease Type, 2023 - 2029, USD Million
TABLE 380 South Korea Gastric Cancer Market by Distribution Channel, 2019 - 2022, USD Million
TABLE 381 South Korea Gastric Cancer Market by Distribution Channel, 2023 - 2029, USD Million
TABLE 382 South Korea Gastric Cancer Market by Drug Class, 2019 - 2022, USD Million
TABLE 383 South Korea Gastric Cancer Market by Drug Class, 2023 - 2029, USD Million
TABLE 384 Singapore Gastric Cancer Market, 2019 - 2022, USD Million
TABLE 385 Singapore Gastric Cancer Market, 2023 - 2029, USD Million
TABLE 386 Singapore Gastric Cancer Market by Route of Administration, 2019 - 2022, USD Million
TABLE 387 Singapore Gastric Cancer Market by Route of Administration, 2023 - 2029, USD Million
TABLE 388 Singapore Gastric Cancer Market by Treatment Type, 2019 - 2022, USD Million
TABLE 389 Singapore Gastric Cancer Market by Treatment Type, 2023 - 2029, USD Million
TABLE 390 Singapore Gastric Cancer Market by Disease Type, 2019 - 2022, USD Million
TABLE 391 Singapore Gastric Cancer Market by Disease Type, 2023 - 2029, USD Million
TABLE 392 Singapore Gastric Cancer Market by Distribution Channel, 2019 - 2022, USD Million
TABLE 393 Singapore Gastric Cancer Market by Distribution Channel, 2023 - 2029, USD Million
TABLE 394 Singapore Gastric Cancer Market by Drug Class, 2019 - 2022, USD Million
TABLE 395 Singapore Gastric Cancer Market by Drug Class, 2023 - 2029, USD Million
TABLE 396 Malaysia Gastric Cancer Market, 2019 - 2022, USD Million
TABLE 397 Malaysia Gastric Cancer Market, 2023 - 2029, USD Million
TABLE 398 Malaysia Gastric Cancer Market by Route of Administration, 2019 - 2022, USD Million
TABLE 399 Malaysia Gastric Cancer Market by Route of Administration, 2023 - 2029, USD Million
TABLE 400 Malaysia Gastric Cancer Market by Treatment Type, 2019 - 2022, USD Million
TABLE 401 Malaysia Gastric Cancer Market by Treatment Type, 2023 - 2029, USD Million
TABLE 402 Malaysia Gastric Cancer Market by Disease Type, 2019 - 2022, USD Million
TABLE 403 Malaysia Gastric Cancer Market by Disease Type, 2023 - 2029, USD Million
TABLE 404 Malaysia Gastric Cancer Market by Distribution Channel, 2019 - 2022, USD Million
TABLE 405 Malaysia Gastric Cancer Market by Distribution Channel, 2023 - 2029, USD Million
TABLE 406 Malaysia Gastric Cancer Market by Drug Class, 2019 - 2022, USD Million
TABLE 407 Malaysia Gastric Cancer Market by Drug Class, 2023 - 2029, USD Million
TABLE 408 Rest of Asia Pacific Gastric Cancer Market, 2019 - 2022, USD Million
TABLE 409 Rest of Asia Pacific Gastric Cancer Market, 2023 - 2029, USD Million
TABLE 410 Rest of Asia Pacific Gastric Cancer Market by Route of Administration, 2019 - 2022, USD Million
TABLE 411 Rest of Asia Pacific Gastric Cancer Market by Route of Administration, 2023 - 2029, USD Million
TABLE 412 Rest of Asia Pacific Gastric Cancer Market by Treatment Type, 2019 - 2022, USD Million
TABLE 413 Rest of Asia Pacific Gastric Cancer Market by Treatment Type, 2023 - 2029, USD Million
TABLE 414 Rest of Asia Pacific Gastric Cancer Market by Disease Type, 2019 - 2022, USD Million
TABLE 415 Rest of Asia Pacific Gastric Cancer Market by Disease Type, 2023 - 2029, USD Million
TABLE 416 Rest of Asia Pacific Gastric Cancer Market by Distribution Channel, 2019 - 2022, USD Million
TABLE 417 Rest of Asia Pacific Gastric Cancer Market by Distribution Channel, 2023 - 2029, USD Million
TABLE 418 Rest of Asia Pacific Gastric Cancer Market by Drug Class, 2019 - 2022, USD Million
TABLE 419 Rest of Asia Pacific Gastric Cancer Market by Drug Class, 2023 - 2029, USD Million
TABLE 420 LAMEA Gastric Cancer Market, 2019 - 2022, USD Million
TABLE 421 LAMEA Gastric Cancer Market, 2023 - 2029, USD Million
TABLE 422 LAMEA Gastric Cancer Market by Route of Administration, 2019 - 2022, USD Million
TABLE 423 LAMEA Gastric Cancer Market by Route of Administration, 2023 - 2029, USD Million
TABLE 424 LAMEA Injectable Market by Country, 2019 - 2022, USD Million
TABLE 425 LAMEA Injectable Market by Country, 2023 - 2029, USD Million
TABLE 426 LAMEA Oral Market by Country, 2019 - 2022, USD Million
TABLE 427 LAMEA Oral Market by Country, 2023 - 2029, USD Million
TABLE 428 LAMEA Gastric Cancer Market by Treatment Type, 2019 - 2022, USD Million
TABLE 429 LAMEA Gastric Cancer Market by Treatment Type, 2023 - 2029, USD Million
TABLE 430 LAMEA Chemotherapy Market by Country, 2019 - 2022, USD Million
TABLE 431 LAMEA Chemotherapy Market by Country, 2023 - 2029, USD Million
TABLE 432 LAMEA Targeted Therapy Market by Country, 2019 - 2022, USD Million
TABLE 433 LAMEA Targeted Therapy Market by Country, 2023 - 2029, USD Million
TABLE 434 LAMEA Immunotherapy Market by Country, 2019 - 2022, USD Million
TABLE 435 LAMEA Immunotherapy Market by Country, 2023 - 2029, USD Million
TABLE 436 LAMEA Radiation Therapy & Surgery Market by Country, 2019 - 2022, USD Million
TABLE 437 LAMEA Radiation Therapy & Surgery Market by Country, 2023 - 2029, USD Million
TABLE 438 LAMEA Gastric Cancer Market by Disease Type, 2019 - 2022, USD Million
TABLE 439 LAMEA Gastric Cancer Market by Disease Type, 2023 - 2029, USD Million
TABLE 440 LAMEA Adenocarcinoma Market by Country, 2019 - 2022, USD Million
TABLE 441 LAMEA Adenocarcinoma Market by Country, 2023 - 2029, USD Million
TABLE 442 LAMEA Carcinoid Tumor Market by Country, 2019 - 2022, USD Million
TABLE 443 LAMEA Carcinoid Tumor Market by Country, 2023 - 2029, USD Million
TABLE 444 LAMEA Gastrointestinal Stromal Tumor Market by Country, 2019 - 2022, USD Million
TABLE 445 LAMEA Gastrointestinal Stromal Tumor Market by Country, 2023 - 2029, USD Million
TABLE 446 LAMEA Lymphoma Market by Country, 2019 - 2022, USD Million
TABLE 447 LAMEA Lymphoma Market by Country, 2023 - 2029, USD Million
TABLE 448 LAMEA Others Market by Country, 2019 - 2022, USD Million
TABLE 449 LAMEA Others Market by Country, 2023 - 2029, USD Million
TABLE 450 LAMEA Gastric Cancer Market by Distribution Channel, 2019 - 2022, USD Million
TABLE 451 LAMEA Gastric Cancer Market by Distribution Channel, 2023 - 2029, USD Million
TABLE 452 LAMEA Specialty & Retail Pharmacies Market by Country, 2019 - 2022, USD Million
TABLE 453 LAMEA Specialty & Retail Pharmacies Market by Country, 2023 - 2029, USD Million
TABLE 454 LAMEA Hospital Pharmacies Market by Country, 2019 - 2022, USD Million
TABLE 455 LAMEA Hospital Pharmacies Market by Country, 2023 - 2029, USD Million
TABLE 456 LAMEA Others Market by Country, 2019 - 2022, USD Million
TABLE 457 LAMEA Others Market by Country, 2023 - 2029, USD Million
TABLE 458 LAMEA Gastric Cancer Market by Drug Class, 2019 - 2022, USD Million
TABLE 459 LAMEA Gastric Cancer Market by Drug Class, 2023 - 2029, USD Million
TABLE 460 LAMEA PD-1/PD-L1 Inhibitors Market by Country, 2019 - 2022, USD Million
TABLE 461 LAMEA PD-1/PD-L1 Inhibitors Market by Country, 2023 - 2029, USD Million
TABLE 462 LAMEA HER2 Antagonists Market by Country, 2019 - 2022, USD Million
TABLE 463 LAMEA HER2 Antagonists Market by Country, 2023 - 2029, USD Million
TABLE 464 LAMEA VEGFR2 Antagonists Market by Country, 2019 - 2022, USD Million
TABLE 465 LAMEA VEGFR2 Antagonists Market by Country, 2023 - 2029, USD Million
TABLE 466 LAMEA Others Market by Country, 2019 - 2022, USD Million
TABLE 467 LAMEA Others Market by Country, 2023 - 2029, USD Million
TABLE 468 LAMEA Gastric Cancer Market by Country, 2019 - 2022, USD Million
TABLE 469 LAMEA Gastric Cancer Market by Country, 2023 - 2029, USD Million
TABLE 470 Brazil Gastric Cancer Market, 2019 - 2022, USD Million
TABLE 471 Brazil Gastric Cancer Market, 2023 - 2029, USD Million
TABLE 472 Brazil Gastric Cancer Market by Route of Administration, 2019 - 2022, USD Million
TABLE 473 Brazil Gastric Cancer Market by Route of Administration, 2023 - 2029, USD Million
TABLE 474 Brazil Gastric Cancer Market by Treatment Type, 2019 - 2022, USD Million
TABLE 475 Brazil Gastric Cancer Market by Treatment Type, 2023 - 2029, USD Million
TABLE 476 Brazil Gastric Cancer Market by Disease Type, 2019 - 2022, USD Million
TABLE 477 Brazil Gastric Cancer Market by Disease Type, 2023 - 2029, USD Million
TABLE 478 Brazil Gastric Cancer Market by Distribution Channel, 2019 - 2022, USD Million
TABLE 479 Brazil Gastric Cancer Market by Distribution Channel, 2023 - 2029, USD Million
TABLE 480 Brazil Gastric Cancer Market by Drug Class, 2019 - 2022, USD Million
TABLE 481 Brazil Gastric Cancer Market by Drug Class, 2023 - 2029, USD Million
TABLE 482 Argentina Gastric Cancer Market, 2019 - 2022, USD Million
TABLE 483 Argentina Gastric Cancer Market, 2023 - 2029, USD Million
TABLE 484 Argentina Gastric Cancer Market by Route of Administration, 2019 - 2022, USD Million
TABLE 485 Argentina Gastric Cancer Market by Route of Administration, 2023 - 2029, USD Million
TABLE 486 Argentina Gastric Cancer Market by Treatment Type, 2019 - 2022, USD Million
TABLE 487 Argentina Gastric Cancer Market by Treatment Type, 2023 - 2029, USD Million
TABLE 488 Argentina Gastric Cancer Market by Disease Type, 2019 - 2022, USD Million
TABLE 489 Argentina Gastric Cancer Market by Disease Type, 2023 - 2029, USD Million
TABLE 490 Argentina Gastric Cancer Market by Distribution Channel, 2019 - 2022, USD Million
TABLE 491 Argentina Gastric Cancer Market by Distribution Channel, 2023 - 2029, USD Million
TABLE 492 Argentina Gastric Cancer Market by Drug Class, 2019 - 2022, USD Million
TABLE 493 Argentina Gastric Cancer Market by Drug Class, 2023 - 2029, USD Million
TABLE 494 UAE Gastric Cancer Market, 2019 - 2022, USD Million
TABLE 495 UAE Gastric Cancer Market, 2023 - 2029, USD Million
TABLE 496 UAE Gastric Cancer Market by Route of Administration, 2019 - 2022, USD Million
TABLE 497 UAE Gastric Cancer Market by Route of Administration, 2023 - 2029, USD Million
TABLE 498 UAE Gastric Cancer Market by Treatment Type, 2019 - 2022, USD Million
TABLE 499 UAE Gastric Cancer Market by Treatment Type, 2023 - 2029, USD Million
TABLE 500 UAE Gastric Cancer Market by Disease Type, 2019 - 2022, USD Million
TABLE 501 UAE Gastric Cancer Market by Disease Type, 2023 - 2029, USD Million
TABLE 502 UAE Gastric Cancer Market by Distribution Channel, 2019 - 2022, USD Million
TABLE 503 UAE Gastric Cancer Market by Distribution Channel, 2023 - 2029, USD Million
TABLE 504 UAE Gastric Cancer Market by Drug Class, 2019 - 2022, USD Million
TABLE 505 UAE Gastric Cancer Market by Drug Class, 2023 - 2029, USD Million
TABLE 506 Saudi Arabia Gastric Cancer Market, 2019 - 2022, USD Million
TABLE 507 Saudi Arabia Gastric Cancer Market, 2023 - 2029, USD Million
TABLE 508 Saudi Arabia Gastric Cancer Market by Route of Administration, 2019 - 2022, USD Million
TABLE 509 Saudi Arabia Gastric Cancer Market by Route of Administration, 2023 - 2029, USD Million
TABLE 510 Saudi Arabia Gastric Cancer Market by Treatment Type, 2019 - 2022, USD Million
TABLE 511 Saudi Arabia Gastric Cancer Market by Treatment Type, 2023 - 2029, USD Million
TABLE 512 Saudi Arabia Gastric Cancer Market by Disease Type, 2019 - 2022, USD Million
TABLE 513 Saudi Arabia Gastric Cancer Market by Disease Type, 2023 - 2029, USD Million
TABLE 514 Saudi Arabia Gastric Cancer Market by Distribution Channel, 2019 - 2022, USD Million
TABLE 515 Saudi Arabia Gastric Cancer Market by Distribution Channel, 2023 - 2029, USD Million
TABLE 516 Saudi Arabia Gastric Cancer Market by Drug Class, 2019 - 2022, USD Million
TABLE 517 Saudi Arabia Gastric Cancer Market by Drug Class, 2023 - 2029, USD Million
TABLE 518 South Africa Gastric Cancer Market, 2019 - 2022, USD Million
TABLE 519 South Africa Gastric Cancer Market, 2023 - 2029, USD Million
TABLE 520 South Africa Gastric Cancer Market by Route of Administration, 2019 - 2022, USD Million
TABLE 521 South Africa Gastric Cancer Market by Route of Administration, 2023 - 2029, USD Million
TABLE 522 South Africa Gastric Cancer Market by Treatment Type, 2019 - 2022, USD Million
TABLE 523 South Africa Gastric Cancer Market by Treatment Type, 2023 - 2029, USD Million
TABLE 524 South Africa Gastric Cancer Market by Disease Type, 2019 - 2022, USD Million
TABLE 525 South Africa Gastric Cancer Market by Disease Type, 2023 - 2029, USD Million
TABLE 526 South Africa Gastric Cancer Market by Distribution Channel, 2019 - 2022, USD Million
TABLE 527 South Africa Gastric Cancer Market by Distribution Channel, 2023 - 2029, USD Million
TABLE 528 South Africa Gastric Cancer Market by Drug Class, 2019 - 2022, USD Million
TABLE 529 South Africa Gastric Cancer Market by Drug Class, 2023 - 2029, USD Million
TABLE 530 Nigeria Gastric Cancer Market, 2019 - 2022, USD Million
TABLE 531 Nigeria Gastric Cancer Market, 2023 - 2029, USD Million
TABLE 532 Nigeria Gastric Cancer Market by Route of Administration, 2019 - 2022, USD Million
TABLE 533 Nigeria Gastric Cancer Market by Route of Administration, 2023 - 2029, USD Million
TABLE 534 Nigeria Gastric Cancer Market by Treatment Type, 2019 - 2022, USD Million
TABLE 535 Nigeria Gastric Cancer Market by Treatment Type, 2023 - 2029, USD Million
TABLE 536 Nigeria Gastric Cancer Market by Disease Type, 2019 - 2022, USD Million
TABLE 537 Nigeria Gastric Cancer Market by Disease Type, 2023 - 2029, USD Million
TABLE 538 Nigeria Gastric Cancer Market by Distribution Channel, 2019 - 2022, USD Million
TABLE 539 Nigeria Gastric Cancer Market by Distribution Channel, 2023 - 2029, USD Million
TABLE 540 Nigeria Gastric Cancer Market by Drug Class, 2019 - 2022, USD Million
TABLE 541 Nigeria Gastric Cancer Market by Drug Class, 2023 - 2029, USD Million
TABLE 542 Rest of LAMEA Gastric Cancer Market, 2019 - 2022, USD Million
TABLE 543 Rest of LAMEA Gastric Cancer Market, 2023 - 2029, USD Million
TABLE 544 Rest of LAMEA Gastric Cancer Market by Route of Administration, 2019 - 2022, USD Million
TABLE 545 Rest of LAMEA Gastric Cancer Market by Route of Administration, 2023 - 2029, USD Million
TABLE 546 Rest of LAMEA Gastric Cancer Market by Treatment Type, 2019 - 2022, USD Million
TABLE 547 Rest of LAMEA Gastric Cancer Market by Treatment Type, 2023 - 2029, USD Million
TABLE 548 Rest of LAMEA Gastric Cancer Market by Disease Type, 2019 - 2022, USD Million
TABLE 549 Rest of LAMEA Gastric Cancer Market by Disease Type, 2023 - 2029, USD Million
TABLE 550 Rest of LAMEA Gastric Cancer Market by Distribution Channel, 2019 - 2022, USD Million
TABLE 551 Rest of LAMEA Gastric Cancer Market by Distribution Channel, 2023 - 2029, USD Million
TABLE 552 Rest of LAMEA Gastric Cancer Market by Drug Class, 2019 - 2022, USD Million
TABLE 553 Rest of LAMEA Gastric Cancer Market by Drug Class, 2023 - 2029, USD Million
TABLE 554 Key Information - Novartis AG
TABLE 555 Key Information - Pfizer, Inc.
TABLE 556 key information - Viatris, Inc.
TABLE 557 KEY INFORMATION - F. Hoffmann-La Roche Ltd.
TABLE 558 Key Information - Eli Lilly And Company
TABLE 559 KEY INFORMATION - Merck & Co., Inc.
TABLE 560 Key Information - Teva Pharmaceuticals Industries Ltd.
TABLE 561 Key Information - Bristol Myers Squibb Company
TABLE 562 Key Information - Celltrion Healthcare Co., Ltd.
TABLE 563 Key Information - Samsung Biologics Co., Ltd.

List of Figures

FIG 1 Methodology for the research
FIG 2 KBV Cardinal Matrix
FIG 3 Key Leading Strategies: Percentage Distribution (2019-2023)
FIG 4 Global Gastric Cancer Market share by Route of Administration, 2022
FIG 5 Global Gastric Cancer Market share by Route of Administration, 2029
FIG 6 Global Gastric Cancer Market by Route of Administration, 2019 - 2029, USD Million
FIG 7 Global Gastric Cancer Market share by Treatment Type, 2022
FIG 8 Global Gastric Cancer Market share by Treatment Type, 2029
FIG 9 Global Gastric Cancer Market by Treatment Type, 2019 - 2029, USD Million
FIG 10 Global Gastric Cancer Market share by Disease Type, 2022
FIG 11 Global Gastric Cancer Market share by Disease Type, 2029
FIG 12 Global Gastric Cancer Market by Disease Type, 2019 - 2029, USD Million
FIG 13 Global Gastric Cancer Market share by Distribution Channel, 2022
FIG 14 Global Gastric Cancer Market share by Distribution Channel, 2029
FIG 15 Global Gastric Cancer Market by Distribution Channel, 2019 - 2029, USD Million
FIG 16 Global Gastric Cancer Market share by Drug Class, 2022
FIG 17 Global Gastric Cancer Market share by Drug Class, 2029
FIG 18 Global Gastric Cancer Market by Drug Class, 2019 - 2029, USD Million
FIG 19 Global Gastric Cancer Market share by Region, 2022
FIG 20 Global Gastric Cancer Market share by Region, 2029
FIG 21 Global Gastric Cancer Market by Region, 2019 - 2029, USD Million
FIG 22 Recent strategies and developments: Viatris, Inc.
FIG 23 Recent strategies and developments: F. Hoffmann-La Roche Ltd.
FIG 24 Recent strategies and developments: Teva Pharmaceuticals Industries Ltd.
FIG 25 Recent strategies and developments: Samsung Biologics Co., Ltd.

The Global Gastric Cancer Market size is expected to reach $6.9 billion by 2029, rising at a market growth of 17.6% CAGR during the forecast period.

The cells lining the stomach are where gastric cancer, also known as stomach cancer, first develops. Abdominal pain, vomiting, nausea, bloating, and weight loss can all be signs of gastric cancer. Surgery, radiation therapy, chemotherapy, or a combination of these treatments are all possible forms of treatment for gastric cancer.

Cancer develops when the body's cells start to proliferate out of control. Cancerous cells can develop in almost any body portion and spread to other organs. Usually, gastric cancers grow slowly over several decades. Precancerous alterations frequently appear in the inner mucosa of the stomach before genuine cancer develops. Since these early alterations rarely have symptoms, they may go unnoticed.

Different parts of the stomach can develop cancer at different times, which can result in a variety of symptoms and prognoses. Treatment choices may vary depending on the location of the cancer. For instance, malignancies that develop into or begin at the GE junction are often staged and treated similarly to esophageal tumors. The mucosa, the stomach's innermost lining, contains gland cells that give rise to these malignancies.

The intestinal type and diffuse type of stomach adenocarcinomas are the two basic forms. The likelihood of specific gene alterations in cancer cells increases the possibility that they can be treated with targeted medication therapy. The diffuse form typically spreads more rapidly. It is less frequent than the intestinal variety, and it is frequently more challenging to treat.

COVID-19 Impact Analysis

Delays in diagnosis & treatment have been the primary effects of the COVID-19 pandemic on gastric cancer. Delays in cancer diagnosis & treatment were the result, and they can significantly affect how patients turn out. Cancer research, particularly clinical trials looking at novel treatments for gastric cancer, has also been hampered by the pandemic. Due to COVID-19 limits, numerous clinical trials were postponed or suspended, which may be slowing down the creation of new treatments for the illness. However, the severe cases were being treated during the pandemic period. Considering these elements, the gastric cancer market witnessed a moderate impact due to COVID-19.

Market Growth Factors

Growing acceptance of targeted therapy and immunotherapy and introduction of new drugs

The number of targeted medications and immunotherapy treatments being developed and introduced into the market has increased due to a better understanding of the disease's molecular foundation. Since 2010, HER-2-specific medications, such as Herceptin, have been marketed. EGFR and PD-1 targeted therapy and immunotherapies are currently being created to treat gastric cancer. Furthermore, the market for gastric cancer is also anticipated to be driven by the approval and subsequent release of medications in the clinical pipeline aiding the gastric cancer market growth.

Rising Prevalence of Gastric Cancer

Gastric cancer is the most prevalent cancer type in Eastern Asia. 2020 saw an anticipated 1.1 million new cases of stomach cancer and 770 000 gastric cancer-related deaths, with male incidence rates often being twice as high as females. During the forecast period, it is anticipated that the rising prevalence of gastric carcinoma will increase demand for gastric cancer treatments and make them one of the most popular market trends for stomach cancer treatments. During the forecast period, this is expected to help the growth of the gastric cancer market.

Market Restraining Factors

Limited treatment option combined with their associated side effects

Treating cancer using chemotherapy, radiation therapy, or a combination of the two and with surgery is possible. The medications used in chemotherapy function by attacking rapidly dividing cancer cells; however, they can also harm healthy cells, resulting in unpleasant side effects such as nausea, vomiting, and exhaustion. In the next years, it is anticipated that this aspect will function as a barrier to the demand in the market. It is projected that factors such as high therapy costs and relatively limited availability of medications for the treatment of stomach cancer would work together to impede the growth of the gastric cancer market throughout the forecasted period.

Disease Type Outlook

Based on disease type, the gastric cancer market is characterized into adenocarcinoma, lymphoma, gastrointestinal stromal tumor, carcinoid tumor, and others. The lymphoma segment covered a considerable revenue share in the gastric cancer market in 2022. The immune system's lymphocytes are where these tumors develop in the first place. There are some lymphomas that can begin in the stomach wall, while most lymphomas begin in other areas of the body. Depending on the lymphoma type and other variables, these tumors can be treated and have good prognoses. The rising awareness of the lymphoma are predicted to support the segment's expansion.

Treatment Type Outlook

On the basis of treatment type, the gastric cancer market is classified into immunotherapy, targeted therapy, chemotherapy, and radiation therapy & surgery. The targeted therapy segment acquired a substantial revenue share in the gastric cancer market in 2022. With targeted therapy, cancer patients receive treatment by having pharmaceuticals that specifically target the genes or proteins that the cancer cells have. Targeted therapy for cancer comes in various forms, including hormonal treatments, gene expression regulators, angiogenesis inhibitors, apoptosis inducers, signal transduction inhibitors, and several more.

Drug Class Outlook

By drug class, the gastric cancer market is divided into PD-1/PD-L1 inhibitors, HER2 antagonists, VEGFR2 antagonists, and others. In 2022, the PD-1/PD-L1 inhibitors segment dominated the gastric cancer market with the maximum revenue share. Immune checkpoint proteins such as programmed cell death protein 1 (PD-1) and PD-L1 often aid in preventing overactive immune responses that may harm healthy tissues. For the treatment of severe or metastatic gastric cancer, a number of PD-1/PD-L1 inhibitors, such as nivolumab, pembrolizumab, and atezolizumab, have been licensed. In patients with advanced gastric cancer, several medications have demonstrated effectiveness in extending survival and slowing tumor growth

Route of Administration Outlook

Based on route of administration, the gastric cancer market is segmented into oral and injectable. In 2022, the injectable segment registered the maximum revenue share in the gastric cancer market. Since injectable pharmaceuticals are administered directly into the bloodstream, they can be absorbed faster than oral medicines. This helps individuals with advanced or metastatic stomach cancer, where quick action may be required. More of the drug can reach its target site when it is administered intravenously, which increases bioavailability. Less side effects and better therapeutic outcomes may arise from this.

Distribution Channel Outlook

On the basis of distribution channel, the gastric cancer market is classified into specialty & retail pharmacies, hospital pharmacies, and others. The hospital pharmacies segment projected a prominent revenue share in the gastric cancer market in 2022. The creation of government-sponsored hospitals pharmacies as well as advantageous reimbursement are the main causes of the hospital pharmacy segment's growth. These reasons together with the strong support the government has provided for cancer treatment. The segment is also predicted to expand as a result of the growing patient pool, growing prevalence of stomach cancer, and increasing number of cancer treatment facilities.

Regional Outlook

Region wise, the gastric cancer market is analyzed across North America, Europe, Asia Pacific, and LAMEA. In 2022, the Asia Pacific region led the gastric cancer market by generating the largest revenue share. The expansion of the market is being driven by the rise in the geriatric population in the Asia-Pacific region. The demand for gastric cancer diagnostics has been driven by the prevalence of gastrointestinal tumors and lymphomas. Furthermore, the rising case of gastric cancer in the region is anticipated to propel the market growth in the Asia Pacific during the projected period.

The major strategies followed by the market participants are Partnerships. Based on the Analysis presented in the Cardinal matrix; Pfizer, Inc. is the major forerunner in the Gastric Cancer Market. Companies such as Merck & Co., Inc., Teva Pharmaceutical Industries Ltd., Eli Lilly and Company are some of the key innovators in Gastric Cancer Market.

The market research report covers the analysis of key stake holders of the market. Key companies profiled in the report include Novartis AG, Pfizer, Inc., Viatris, Inc. (Mylan N.V.), F. Hoffmann-La Roche Ltd., Eli Lilly And Company, Merck & Co., Inc., Teva Pharmaceuticals Industries Ltd., Bristol Myers Squibb Company, Celltrion Healthcare Co., Ltd., and Samsung Biologics Co., Ltd. (Samsung Bioepis Co., Ltd.).

Strategies deployed in Gastric Cancer Market

Partnerships, Collaborations, and Agreements:

Feb-2023: Pfizer came into collaboration with Tempus, a technology company focused on advancing precision medicine through the practical application of artificial intelligence in healthcare. Following the collaboration, Pfizer would access Tempus' AI-based platform and multimodal data library, together with its clinical trial matching program and companion diagnostic development capabilities.

Jan-2023: Roche signed an agreement with CHEPLAPHARM, following which the latter company took the commercial rights from Roche for Xeloda (capecitabin) in China. Early in 2022, CHEPLAPHARM already had the rights for the extremely potent anti-cancer drug in every country except China and Japan. By incorporating China, CHEPLAPHARM improves its cancer product line and increases its market share in the world's second-largest pharmaceutical market. In 1997, Xeloda® received approval in China for use as a prescription drug. Shanghai Roche Pharmaceuticals got permission from China's State FDA in 2007 to treat advanced gastric cancer, metastatic breast cancer, and colorectal cancer.

Jan-2023: Roche extended its collaboration with CARsgen Therapeutics Holdings Limited, a manufacturer of innovative therapies for the treatment of solid tumors and hematologic malignancies. Following the expansion, the companies aim to evaluate CARsgen's investigational drug AB011, the first humanized monoclonal antibody against Claudin18.2 (CLDN18.2) that received IND clearance across the world, together with atezolizumab, Roche's PD-L1 checkpoint inhibitor, along with standard-of-care chemotherapy in patients with gastric or gastroesophageal junction carcinoma. In addition, Roche will be in charge of operating and conducting the research while both businesses would split the costs of the study's AB011 treatment arms.

Marr-2022: Celltrion Healthcare announced that they have got the tender in Brazil, from the Brazilian Federal Government to procure the world's first monoclonal antibody biosimilar Remsima (infliximab). Additionally, the company has won 12 State bids in Brazil to supply Remsima, including the largest state in Brazil Sao Paulo.

Mar-2022: Bristol Myers Squibb announced a clinical collaboration with Transcenta Holding Limited, a clinical-stage biopharmaceutical company, for the evaluation of the combination of TST001, an investigational humanized monoclonal antibody targeting Claudin18.2 created by Transcenta, with Opdivo® (nivolumab), Bristol Myers Squibb's anti-PD-1 therapy. This has been indicated for the treatment of unresectable locally advanced or metastatic gastric cancer or gastroesophageal junction cancer (GC/GEJ).

Feb-2022: Bristol Myers Squibb and Ono Pharmaceutical signed an agreement with Prime Research Institute for Medical RWD, Inc. for an industry-sponsored, large-scale, multi-institutional clinical research on gastric cancer patients treated with Opdivo together with chemotherapy. The study would utilize the PRiME-R's "CyberOncology®" data entry support system, which standardizes, organizes, manages, and integrates real-world data in routine cancer clinical practice.

Sep-2021: Roche Diagnostics International came into an agreement with Medical EarlySign, a company focused on developing ML-based decision support tools, for commercializing an AI tool that would detect cancer early. Following the agreement, the companies create the product, clinically validate it, and then market it. The companies would initially concentrate on the field of stomach cancer. EarlySign's software, which includes lab findings, EHR data, and other clinical care, is used in the clinical decision support tool.

Jun-2021: Eli Lilly and Company signed a clinical trial and supply agreement with ALX Oncology, a clinical-stage immuno-oncology company. Following the agreement, the companies aimed to evaluate the combination of Lilly's anti-VEGFR2 antibody, and ALX148, a next-generation CD47 blocker, for the treatment of HER2-positive gastric cancer or gastroesophageal junction cancer patients.

Feb-2021: Novartis Pharma announced a collaboration and license agreement with BeiGene, Ltd., a biotechnology company engaged in the development and commercialization of innovative medicines. The agreement was focused on developing, manufacturing, and commercializing BeiGene's anti-PD-1 antibody tislelizumab in the US, Mexico, Canada, and member countries of the European region, Norway, United Kingdom, Iceland, Switzerland, Russia, Liechtenstein, and Japan. Additionally, both businesses may perform clinical studies around the world to investigate pairings of tislelizumab with other cancer therapies, and BeiGene has the option to co-develop the medicine in North America with Novartis' financial support.

Product Launches and Product Expansions:

Aug-2020: Samsung Bioepis unveiled Ontruzant (trastuzumab), a biosimilar referencing Roche's Herceptin, in Brazil. Ontruzant (150 mg single-dose vials) has been authorized for the treatment of advanced gastric cancer, metastatic HER2-overexpressing breast cancer, and early HER2-overexpressing breast cancer by the Agencia Nacional de Vigilancia Sanitaria (ANVISA), the country's health regulatory body. It was launched in the United States in April 2020.

Mar-2020: Teva Pharmaceuticals USA, Inc., a division of Teva, together with Celltrion Healthcare, announced the availability of HERZUMA®1 (trastuzumab-pkrb) for Injection, a biosimilar to HERCEPTIN®1 in the United States. HERZUMA is approved in combination with cisplatin, capecitabine, or 5-fluorouracil for the treatment of patients with HER2-overexpressing metastatic gastric or gastroesophageal junction adenocarcinoma who have not previously undergone treatment for metastatic disease.

Approvals & Trials:

Jun-2022: Eli Lilly and Company and Innovent Biologics, Inc., a biopharmaceutical company, received approval from the National Medical Products Administration (NMPA) of China for the supplemental New Drug Application (sNDA) for TYVYT® (sintilimab injection) together with fluorouracil and platinum-based chemotherapy for the first-line treatment of unresectable, locally advanced, recurrent or metastatic gastric or gastroesophageal junction adenocarcinoma.

Feb-2022: Samsung Bioepis got approval for ONTRUZANT® (also known as SB3), a biosimilar referencing Herceptin ®i (Trastuzumab) from Health Canada. This biosimilar is used for the treatment of Early Breast Cancer, metastatic gastric cancer (MGC), and Metastatic Breast Cancer (MBC), among adults.

Oct-2021: Bristol Myers Squibb got approval from European Commission for Opdivo (nivolumab) in combination with fluoropyrimidine- and platinum-based combination chemotherapy. This biosimilar is utilized for first-line treatment of adult patients with gastroesophageal junction (GEJ), HER2-negative advanced or metastatic gastric, or esophageal adenocarcinoma (EAC) whose tumors express PD-L1 with a combined positive score (CPS) ≥ 5.

Apr-2021: Bristol Myers Squibb received approval from the U.S. Food and Drug Administration (FDA) for Opdivo (nivolumab) (injection for intravenous use), in combination with fluoropyrimidine- and platinum-containing chemotherapy. This biosimilar is utilized for the treatment of patients with gastroesophageal junction cancer, advanced or metastatic gastric cancer, and esophageal adenocarcinoma, regardless of PD-L1 expression status.

Scope of the Study

Market Segments covered in the Report:

By Route of Administration

Injectable
Oral

By Treatment Type

Chemotherapy
Targeted Therapy
Immunotherapy
Radiation Therapy & Surgery

By Disease Type

Adenocarcinoma
Carcinoid Tumor
Gastrointestinal Stromal Tumor
Lymphoma
Others

By Distribution Channel

Specialty & Retail Pharmacies
Hospital Pharmacies
Others

By Drug Class

PD-1/PD-L1 Inhibitors
HER2 Antagonists
VEGFR2 Antagonists
Others

By Geography

North America
- US
- Canada
- Mexico
- Rest of North America
Europe
- Germany
- UK
- France
- Russia
- Spain
- Italy
- Rest of Europe
Asia Pacific
- China
- Japan
- India
- South Korea
- Singapore
- Malaysia
- Rest of Asia Pacific
LAMEA
- Brazil
- Argentina
- UAE
- Saudi Arabia
- South Africa
- Nigeria
- Rest of LAMEA

Companies Profiled

Novartis AG
Pfizer, Inc.
Viatris, Inc. (Mylan N.V.)
F. Hoffmann-La Roche Ltd.
Eli Lilly And Company
Merck & Co., Inc.
Teva Pharmaceuticals Industries Ltd.
Bristol Myers Squibb Company
Celltrion Healthcare Co., Ltd.
Samsung Biologics Co., Ltd. (Samsung Bioepis Co., Ltd.)

Unique Offerings from KBV Research

Exhaustive coverage
Highest number of market tables and figures
Subscription based model available
Guaranteed best price
Assured post sales research support with 10% customization free

Chapter 1. Market Scope & Methodology

1.1 Market Definition
1.2 Objectives
1.3 Market Scope
1.4 Segmentation
- 1.4.1 Global Gastric Cancer Market, by Route of Administration
- 1.4.2 Global Gastric Cancer Market, by Treatment Type
- 1.4.3 Global Gastric Cancer Market, by Disease Type
- 1.4.4 Global Gastric Cancer Market, by Distribution Channel
- 1.4.5 Global Gastric Cancer Market, by Drug Class
- 1.4.6 Global Gastric Cancer Market, by Geography
1.5 Methodology for the research

Chapter 2. Market Overview

2.1 Introduction
- 2.1.1 Overview
  - 2.1.1.1 Market Composition & Scenario
2.2 Key Factors Impacting the Market
- 2.2.1 Market Drivers
- 2.2.2 Market Restraints

Chapter 3. Competition Analysis - Global

3.1 KBV Cardinal Matrix
3.2 Recent Industry Wide Strategic Developments
- 3.2.1 Partnerships, Collaborations and Agreements
- 3.2.2 Product Launches and Product Expansions
- 3.2.3 Approvals & Trials
3.3 Top Winning Strategies
- 3.3.1 Key Leading Strategies: Percentage Distribution (2019-2023)

Chapter 4. Global Gastric Cancer Market by Route of Administration

4.1 Global Injectable Market by Region
4.2 Global Oral Market by Region

Chapter 5. Global Gastric Cancer Market by Treatment Type

5.1 Global Chemotherapy Market by Region
5.2 Global Targeted Therapy Market by Region
5.3 Global Immunotherapy Market by Region
5.4 Global Radiation Therapy & Surgery Market by Region

Chapter 6. Global Gastric Cancer Market by Disease Type

6.1 Global Adenocarcinoma Market by Region
6.2 Global Carcinoid Tumor Market by Region
6.3 Global Gastrointestinal Stromal Tumor Market by Region
6.4 Global Lymphoma Market by Region
6.5 Global Others Market by Region

Chapter 7. Global Gastric Cancer Market by Distribution Channel

7.1 Global Specialty & Retail Pharmacies Market by Region
7.2 Global Hospital Pharmacies Market by Region
7.3 Global Others Market by Region

Chapter 8. Global Gastric Cancer Market by Drug Class

8.1 Global PD-1/PD-L1 Inhibitors Market by Region
8.2 Global HER2 Antagonists Market by Region
8.3 Global VEGFR2 Antagonists Market by Region
8.4 Global Others Market by Region

Chapter 9. Global Gastric Cancer Market by Region

9.1 North America Gastric Cancer Market
- 9.1.1 North America Gastric Cancer Market by Route of Administration
  - 9.1.1.1 North America Injectable Market by Country
  - 9.1.1.2 North America Oral Market by Country
- 9.1.2 North America Gastric Cancer Market by Treatment Type
  - 9.1.2.1 North America Chemotherapy Market by Country
  - 9.1.2.2 North America Targeted Therapy Market by Country
  - 9.1.2.3 North America Immunotherapy Market by Country
  - 9.1.2.4 North America Radiation Therapy & Surgery Market by Country
- 9.1.3 North America Gastric Cancer Market by Disease Type
  - 9.1.3.1 North America Adenocarcinoma Market by Country
  - 9.1.3.2 North America Carcinoid Tumor Market by Country
  - 9.1.3.3 North America Gastrointestinal Stromal Tumor Market by Country
  - 9.1.3.4 North America Lymphoma Market by Country
  - 9.1.3.5 North America Others Market by Country
- 9.1.4 North America Gastric Cancer Market by Distribution Channel
  - 9.1.4.1 North America Specialty & Retail Pharmacies Market by Country
  - 9.1.4.2 North America Hospital Pharmacies Market by Country
  - 9.1.4.3 North America Others Market by Country
- 9.1.5 North America Gastric Cancer Market by Drug Class
  - 9.1.5.1 North America PD-1/PD-L1 Inhibitors Market by Country
  - 9.1.5.2 North America HER2 Antagonists Market by Country
  - 9.1.5.3 North America VEGFR2 Antagonists Market by Country
  - 9.1.5.4 North America Others Market by Country
- 9.1.6 North America Gastric Cancer Market by Country
  - 9.1.6.1 US Gastric Cancer Market
    - 9.1.6.1.1 US Gastric Cancer Market by Route of Administration
    - 9.1.6.1.2 US Gastric Cancer Market by Treatment Type
    - 9.1.6.1.3 US Gastric Cancer Market by Disease Type
    - 9.1.6.1.4 US Gastric Cancer Market by Distribution Channel
    - 9.1.6.1.5 US Gastric Cancer Market by Drug Class
  - 9.1.6.2 Canada Gastric Cancer Market
    - 9.1.6.2.1 Canada Gastric Cancer Market by Route of Administration
    - 9.1.6.2.2 Canada Gastric Cancer Market by Treatment Type
    - 9.1.6.2.3 Canada Gastric Cancer Market by Disease Type
    - 9.1.6.2.4 Canada Gastric Cancer Market by Distribution Channel
    - 9.1.6.2.5 Canada Gastric Cancer Market by Drug Class
  - 9.1.6.3 Mexico Gastric Cancer Market
    - 9.1.6.3.1 Mexico Gastric Cancer Market by Route of Administration
    - 9.1.6.3.2 Mexico Gastric Cancer Market by Treatment Type
    - 9.1.6.3.3 Mexico Gastric Cancer Market by Disease Type
    - 9.1.6.3.4 Mexico Gastric Cancer Market by Distribution Channel
    - 9.1.6.3.5 Mexico Gastric Cancer Market by Drug Class
  - 9.1.6.4 Rest of North America Gastric Cancer Market
    - 9.1.6.4.1 Rest of North America Gastric Cancer Market by Route of Administration
    - 9.1.6.4.2 Rest of North America Gastric Cancer Market by Treatment Type
    - 9.1.6.4.3 Rest of North America Gastric Cancer Market by Disease Type
    - 9.1.6.4.4 Rest of North America Gastric Cancer Market by Distribution Channel
    - 9.1.6.4.5 Rest of North America Gastric Cancer Market by Drug Class
9.2 Europe Gastric Cancer Market
- 9.2.1 Europe Gastric Cancer Market by Route of Administration
  - 9.2.1.1 Europe Injectable Market by Country
  - 9.2.1.2 Europe Oral Market by Country
- 9.2.2 Europe Gastric Cancer Market by Treatment Type
  - 9.2.2.1 Europe Chemotherapy Market by Country
  - 9.2.2.2 Europe Targeted Therapy Market by Country
  - 9.2.2.3 Europe Immunotherapy Market by Country
  - 9.2.2.4 Europe Radiation Therapy & Surgery Market by Country
- 9.2.3 Europe Gastric Cancer Market by Disease Type
  - 9.2.3.1 Europe Adenocarcinoma Market by Country
  - 9.2.3.2 Europe Carcinoid Tumor Market by Country
  - 9.2.3.3 Europe Gastrointestinal Stromal Tumor Market by Country
  - 9.2.3.4 Europe Lymphoma Market by Country
  - 9.2.3.5 Europe Others Market by Country
- 9.2.4 Europe Gastric Cancer Market by Distribution Channel
  - 9.2.4.1 Europe Specialty & Retail Pharmacies Market by Country
  - 9.2.4.2 Europe Hospital Pharmacies Market by Country
  - 9.2.4.3 Europe Others Market by Country
- 9.2.5 Europe Gastric Cancer Market by Drug Class
  - 9.2.5.1 Europe PD-1/PD-L1 Inhibitors Market by Country
  - 9.2.5.2 Europe HER2 Antagonists Market by Country
  - 9.2.5.3 Europe VEGFR2 Antagonists Market by Country
  - 9.2.5.4 Europe Others Market by Country
- 9.2.6 Europe Gastric Cancer Market by Country
  - 9.2.6.1 Germany Gastric Cancer Market
    - 9.2.6.1.1 Germany Gastric Cancer Market by Route of Administration
    - 9.2.6.1.2 Germany Gastric Cancer Market by Treatment Type
    - 9.2.6.1.3 Germany Gastric Cancer Market by Disease Type
    - 9.2.6.1.4 Germany Gastric Cancer Market by Distribution Channel
    - 9.2.6.1.5 Germany Gastric Cancer Market by Drug Class
  - 9.2.6.2 UK Gastric Cancer Market
    - 9.2.6.2.1 UK Gastric Cancer Market by Route of Administration
    - 9.2.6.2.2 UK Gastric Cancer Market by Treatment Type
    - 9.2.6.2.3 UK Gastric Cancer Market by Disease Type
    - 9.2.6.2.4 UK Gastric Cancer Market by Distribution Channel
    - 9.2.6.2.5 UK Gastric Cancer Market by Drug Class
  - 9.2.6.3 France Gastric Cancer Market
    - 9.2.6.3.1 France Gastric Cancer Market by Route of Administration
    - 9.2.6.3.2 France Gastric Cancer Market by Treatment Type
    - 9.2.6.3.3 France Gastric Cancer Market by Disease Type
    - 9.2.6.3.4 France Gastric Cancer Market by Distribution Channel
    - 9.2.6.3.5 France Gastric Cancer Market by Drug Class
  - 9.2.6.4 Russia Gastric Cancer Market
    - 9.2.6.4.1 Russia Gastric Cancer Market by Route of Administration
    - 9.2.6.4.2 Russia Gastric Cancer Market by Treatment Type
    - 9.2.6.4.3 Russia Gastric Cancer Market by Disease Type
    - 9.2.6.4.4 Russia Gastric Cancer Market by Distribution Channel
    - 9.2.6.4.5 Russia Gastric Cancer Market by Drug Class
  - 9.2.6.5 Spain Gastric Cancer Market
    - 9.2.6.5.1 Spain Gastric Cancer Market by Route of Administration
    - 9.2.6.5.2 Spain Gastric Cancer Market by Treatment Type
    - 9.2.6.5.3 Spain Gastric Cancer Market by Disease Type
    - 9.2.6.5.4 Spain Gastric Cancer Market by Distribution Channel
    - 9.2.6.5.5 Spain Gastric Cancer Market by Drug Class
  - 9.2.6.6 Italy Gastric Cancer Market
    - 9.2.6.6.1 Italy Gastric Cancer Market by Route of Administration
    - 9.2.6.6.2 Italy Gastric Cancer Market by Treatment Type
    - 9.2.6.6.3 Italy Gastric Cancer Market by Disease Type
    - 9.2.6.6.4 Italy Gastric Cancer Market by Distribution Channel
    - 9.2.6.6.5 Italy Gastric Cancer Market by Drug Class
  - 9.2.6.7 Rest of Europe Gastric Cancer Market
    - 9.2.6.7.1 Rest of Europe Gastric Cancer Market by Route of Administration
    - 9.2.6.7.2 Rest of Europe Gastric Cancer Market by Treatment Type
    - 9.2.6.7.3 Rest of Europe Gastric Cancer Market by Disease Type
    - 9.2.6.7.4 Rest of Europe Gastric Cancer Market by Distribution Channel
    - 9.2.6.7.5 Rest of Europe Gastric Cancer Market by Drug Class
9.3 Asia Pacific Gastric Cancer Market
- 9.3.1 Asia Pacific Gastric Cancer Market by Route of Administration
  - 9.3.1.1 Asia Pacific Injectable Market by Country
  - 9.3.1.2 Asia Pacific Oral Market by Country
- 9.3.2 Asia Pacific Gastric Cancer Market by Treatment Type
  - 9.3.2.1 Asia Pacific Chemotherapy Market by Country
  - 9.3.2.2 Asia Pacific Targeted Therapy Market by Country
  - 9.3.2.3 Asia Pacific Immunotherapy Market by Country
  - 9.3.2.4 Asia Pacific Radiation Therapy & Surgery Market by Country
- 9.3.3 Asia Pacific Gastric Cancer Market by Disease Type
  - 9.3.3.1 Asia Pacific Adenocarcinoma Market by Country
  - 9.3.3.2 Asia Pacific Carcinoid Tumor Market by Country
  - 9.3.3.3 Asia Pacific Gastrointestinal Stromal Tumor Market by Country
  - 9.3.3.4 Asia Pacific Lymphoma Market by Country
  - 9.3.3.5 Asia Pacific Others Market by Country
- 9.3.4 Asia Pacific Gastric Cancer Market by Distribution Channel
  - 9.3.4.1 Asia Pacific Specialty & Retail Pharmacies Market by Country
  - 9.3.4.2 Asia Pacific Hospital Pharmacies Market by Country
  - 9.3.4.3 Asia Pacific Others Market by Country
- 9.3.5 Asia Pacific Gastric Cancer Market by Drug Class
  - 9.3.5.1 Asia Pacific PD-1/PD-L1 Inhibitors Market by Country
  - 9.3.5.2 Asia Pacific HER2 Antagonists Market by Country
  - 9.3.5.3 Asia Pacific VEGFR2 Antagonists Market by Country
  - 9.3.5.4 Asia Pacific Others Market by Country
- 9.3.6 Asia Pacific Gastric Cancer Market by Country
  - 9.3.6.1 China Gastric Cancer Market
    - 9.3.6.1.1 China Gastric Cancer Market by Route of Administration
    - 9.3.6.1.2 China Gastric Cancer Market by Treatment Type
    - 9.3.6.1.3 China Gastric Cancer Market by Disease Type
    - 9.3.6.1.4 China Gastric Cancer Market by Distribution Channel
    - 9.3.6.1.5 China Gastric Cancer Market by Drug Class
  - 9.3.6.2 Japan Gastric Cancer Market
    - 9.3.6.2.1 Japan Gastric Cancer Market by Route of Administration
    - 9.3.6.2.2 Japan Gastric Cancer Market by Treatment Type
    - 9.3.6.2.3 Japan Gastric Cancer Market by Disease Type
    - 9.3.6.2.4 Japan Gastric Cancer Market by Distribution Channel
    - 9.3.6.2.5 Japan Gastric Cancer Market by Drug Class
  - 9.3.6.3 India Gastric Cancer Market
    - 9.3.6.3.1 India Gastric Cancer Market by Route of Administration
    - 9.3.6.3.2 India Gastric Cancer Market by Treatment Type
    - 9.3.6.3.3 India Gastric Cancer Market by Disease Type
    - 9.3.6.3.4 India Gastric Cancer Market by Distribution Channel
    - 9.3.6.3.5 India Gastric Cancer Market by Drug Class
  - 9.3.6.4 South Korea Gastric Cancer Market
    - 9.3.6.4.1 South Korea Gastric Cancer Market by Route of Administration
    - 9.3.6.4.2 South Korea Gastric Cancer Market by Treatment Type
    - 9.3.6.4.3 South Korea Gastric Cancer Market by Disease Type
    - 9.3.6.4.4 South Korea Gastric Cancer Market by Distribution Channel
    - 9.3.6.4.5 South Korea Gastric Cancer Market by Drug Class
  - 9.3.6.5 Singapore Gastric Cancer Market
    - 9.3.6.5.1 Singapore Gastric Cancer Market by Route of Administration
    - 9.3.6.5.2 Singapore Gastric Cancer Market by Treatment Type
    - 9.3.6.5.3 Singapore Gastric Cancer Market by Disease Type
    - 9.3.6.5.4 Singapore Gastric Cancer Market by Distribution Channel
    - 9.3.6.5.5 Singapore Gastric Cancer Market by Drug Class
  - 9.3.6.6 Malaysia Gastric Cancer Market
    - 9.3.6.6.1 Malaysia Gastric Cancer Market by Route of Administration
    - 9.3.6.6.2 Malaysia Gastric Cancer Market by Treatment Type
    - 9.3.6.6.3 Malaysia Gastric Cancer Market by Disease Type
    - 9.3.6.6.4 Malaysia Gastric Cancer Market by Distribution Channel
    - 9.3.6.6.5 Malaysia Gastric Cancer Market by Drug Class
  - 9.3.6.7 Rest of Asia Pacific Gastric Cancer Market
    - 9.3.6.7.1 Rest of Asia Pacific Gastric Cancer Market by Route of Administration
    - 9.3.6.7.2 Rest of Asia Pacific Gastric Cancer Market by Treatment Type
    - 9.3.6.7.3 Rest of Asia Pacific Gastric Cancer Market by Disease Type
    - 9.3.6.7.4 Rest of Asia Pacific Gastric Cancer Market by Distribution Channel
    - 9.3.6.7.5 Rest of Asia Pacific Gastric Cancer Market by Drug Class
9.4 LAMEA Gastric Cancer Market
- 9.4.1 LAMEA Gastric Cancer Market by Route of Administration
  - 9.4.1.1 LAMEA Injectable Market by Country
  - 9.4.1.2 LAMEA Oral Market by Country
- 9.4.2 LAMEA Gastric Cancer Market by Treatment Type
  - 9.4.2.1 LAMEA Chemotherapy Market by Country
  - 9.4.2.2 LAMEA Targeted Therapy Market by Country
  - 9.4.2.3 LAMEA Immunotherapy Market by Country
  - 9.4.2.4 LAMEA Radiation Therapy & Surgery Market by Country
- 9.4.3 LAMEA Gastric Cancer Market by Disease Type
  - 9.4.3.1 LAMEA Adenocarcinoma Market by Country
  - 9.4.3.2 LAMEA Carcinoid Tumor Market by Country
  - 9.4.3.3 LAMEA Gastrointestinal Stromal Tumor Market by Country
  - 9.4.3.4 LAMEA Lymphoma Market by Country
  - 9.4.3.5 LAMEA Others Market by Country
- 9.4.4 LAMEA Gastric Cancer Market by Distribution Channel
  - 9.4.4.1 LAMEA Specialty & Retail Pharmacies Market by Country
  - 9.4.4.2 LAMEA Hospital Pharmacies Market by Country
  - 9.4.4.3 LAMEA Others Market by Country
- 9.4.5 LAMEA Gastric Cancer Market by Drug Class
  - 9.4.5.1 LAMEA PD-1/PD-L1 Inhibitors Market by Country
  - 9.4.5.2 LAMEA HER2 Antagonists Market by Country
  - 9.4.5.3 LAMEA VEGFR2 Antagonists Market by Country
  - 9.4.5.4 LAMEA Others Market by Country
- 9.4.6 LAMEA Gastric Cancer Market by Country
  - 9.4.6.1 Brazil Gastric Cancer Market
    - 9.4.6.1.1 Brazil Gastric Cancer Market by Route of Administration
    - 9.4.6.1.2 Brazil Gastric Cancer Market by Treatment Type
    - 9.4.6.1.3 Brazil Gastric Cancer Market by Disease Type
    - 9.4.6.1.4 Brazil Gastric Cancer Market by Distribution Channel
    - 9.4.6.1.5 Brazil Gastric Cancer Market by Drug Class
  - 9.4.6.2 Argentina Gastric Cancer Market
    - 9.4.6.2.1 Argentina Gastric Cancer Market by Route of Administration
    - 9.4.6.2.2 Argentina Gastric Cancer Market by Treatment Type
    - 9.4.6.2.3 Argentina Gastric Cancer Market by Disease Type
    - 9.4.6.2.4 Argentina Gastric Cancer Market by Distribution Channel
    - 9.4.6.2.5 Argentina Gastric Cancer Market by Drug Class
  - 9.4.6.3 UAE Gastric Cancer Market
    - 9.4.6.3.1 UAE Gastric Cancer Market by Route of Administration
    - 9.4.6.3.2 UAE Gastric Cancer Market by Treatment Type
    - 9.4.6.3.3 UAE Gastric Cancer Market by Disease Type
    - 9.4.6.3.4 UAE Gastric Cancer Market by Distribution Channel
    - 9.4.6.3.5 UAE Gastric Cancer Market by Drug Class
  - 9.4.6.4 Saudi Arabia Gastric Cancer Market
    - 9.4.6.4.1 Saudi Arabia Gastric Cancer Market by Route of Administration
    - 9.4.6.4.2 Saudi Arabia Gastric Cancer Market by Treatment Type
    - 9.4.6.4.3 Saudi Arabia Gastric Cancer Market by Disease Type
    - 9.4.6.4.4 Saudi Arabia Gastric Cancer Market by Distribution Channel
    - 9.4.6.4.5 Saudi Arabia Gastric Cancer Market by Drug Class
  - 9.4.6.5 South Africa Gastric Cancer Market
    - 9.4.6.5.1 South Africa Gastric Cancer Market by Route of Administration
    - 9.4.6.5.2 South Africa Gastric Cancer Market by Treatment Type
    - 9.4.6.5.3 South Africa Gastric Cancer Market by Disease Type
    - 9.4.6.5.4 South Africa Gastric Cancer Market by Distribution Channel
    - 9.4.6.5.5 South Africa Gastric Cancer Market by Drug Class
  - 9.4.6.6 Nigeria Gastric Cancer Market
    - 9.4.6.6.1 Nigeria Gastric Cancer Market by Route of Administration
    - 9.4.6.6.2 Nigeria Gastric Cancer Market by Treatment Type
    - 9.4.6.6.3 Nigeria Gastric Cancer Market by Disease Type
    - 9.4.6.6.4 Nigeria Gastric Cancer Market by Distribution Channel
    - 9.4.6.6.5 Nigeria Gastric Cancer Market by Drug Class
  - 9.4.6.7 Rest of LAMEA Gastric Cancer Market
    - 9.4.6.7.1 Rest of LAMEA Gastric Cancer Market by Route of Administration
    - 9.4.6.7.2 Rest of LAMEA Gastric Cancer Market by Treatment Type
    - 9.4.6.7.3 Rest of LAMEA Gastric Cancer Market by Disease Type
    - 9.4.6.7.4 Rest of LAMEA Gastric Cancer Market by Distribution Channel
    - 9.4.6.7.5 Rest of LAMEA Gastric Cancer Market by Drug Class

Chapter 10. Company Profiles

10.1 Novartis AG
- 10.1.1 Company Overview
- 10.1.2 Financial Analysis
- 10.1.3 Segmental and Regional Analysis
- 10.1.4 Research & Development Expense
- 10.1.5 Recent strategies and developments:
  - 10.1.5.1 Partnerships, Collaborations, and Agreements:
10.2 Pfizer, Inc.
- 10.2.1 Company Overview
- 10.2.2 Financial Analysis
- 10.2.3 Regional & Segmental Analysis
- 10.2.4 Research & Development Expense
- 10.2.5 Recent strategies and developments:
  - 10.2.5.1 Partnerships, Collaborations, and Agreements:
10.3 Viatris, Inc. (Mylan N.V.)
- 10.3.1 Company Overview
- 10.3.2 Financial Analysis
- 10.3.3 Segmental Analysis
- 10.3.4 Research & Development Expense
- 10.3.5 Recent strategies and developments:
  - 10.3.5.1 Product Launches and Product Expansions:
  - 10.3.5.2 Approvals & Trials:
10.4 F. Hoffmann-La Roche Ltd.
- 10.4.1 Company Overview
- 10.4.2 Financial Analysis
- 10.4.3 Segmental and Regional Analysis
- 10.4.4 Research & Development Expense
- 10.4.5 Recent strategies and developments:
  - 10.4.5.1 Partnerships, Collaborations, and Agreements:
  - 10.4.5.2 Product Launches and Product Expansions:
10.5 Eli Lilly And Company
- 10.5.1 Company Overview
- 10.5.2 Financial Analysis
- 10.5.3 Regional Analysis
- 10.5.4 Research & Development Expenses
- 10.5.5 Recent strategies and developments:
  - 10.5.5.1 Approvals & Trials:
  - 10.5.5.2 Partnerships, Collaborations, and Agreements:
10.6 Merck & Co., Inc.
- 10.6.1 Company Overview
- 10.6.2 Financial Analysis
- 10.6.3 Segmental and Regional Analysis
- 10.6.4 Research & Development Expenses
- 10.6.5 Recent strategies and developments:
  - 10.6.5.1 Partnerships, Collaborations, and Agreements:
10.7 Teva Pharmaceutical Industries Ltd.
- 10.7.1 Company Overview
- 10.7.2 Financial Analysis
- 10.7.3 Regional Analysis
- 10.7.4 Research & Development Expenses
- 10.7.5 Recent strategies and developments:
  - 10.7.5.1 Product Launches and Product Expansions:
  - 10.7.5.2 Approvals & Trials:
  - 10.7.5.3 Partnerships, Collaborations, and Agreements:
10.8 Bristol Myers Squibb Company
- 10.8.1 Company Overview
- 10.8.2 Financial Analysis
- 10.8.3 Regional Analysis
- 10.8.4 Research & Development Expenses
- 10.8.5 Recent strategies and developments:
  - 10.8.5.1 Partnerships, Collaborations, and Agreements:
  - 10.8.5.2 Approvals & Trials:
10.9 Celltrion Healthcare Co., Ltd.
- 10.9.1 Company Overview
- 10.9.2 Financial Analysis
- 10.9.3 Recent strategies and developments:
  - 10.9.3.1 Partnerships, Collaborations, and Agreements:
10.10. Samsung Biologics Co., Ltd. (Samsung Bioepis Co., Ltd.)
- 10.10.1 Company Overview
- 10.10.2 Financial Analysis
- 10.10.3 Segmental and Regional Analysis
- 10.10.4 Research & Development Expenses
- 10.10.5 Recent strategies and developments:
  - 10.10.5.1 Approvals & Trials:
  - 10.10.5.2 Product Launches and Product Expansions:

胃がんの世界市場規模・シェア・産業動向分析レポート：投与経路別（注射・経口）、治療タイプ別、疾患タイプ別、流通チャネル別、薬剤クラス別、地域別展望・予測、2023～2029年

Global Gastric Cancer Market Size, Share & Industry Trends Analysis Report By Route of Administration (Injectable and Oral), By Treatment Type, By Disease Type, By Distribution Channel, By Drug Class, By Regional Outlook and Forecast, 2023 - 2029

目次

第1章市場範囲と調査手法

第2章市場概要

第3章競合分析- 世界

第4章世界の胃がん市場：投与経路別

第5章世界の胃がん市場：治療タイプ別

第6章世界の胃がん市場：疾患タイプ別

第7章世界の胃がん市場：流通チャネル別

第8章世界の胃がん市場：薬剤クラス別

第9章世界の胃がん市場：地域別

第10章企業プロファイル

LIST OF TABLES

Scope of the Study

Table of Contents

Chapter 1. Market Scope & Methodology

Chapter 2. Market Overview

Chapter 3. Competition Analysis - Global

Chapter 4. Global Gastric Cancer Market by Route of Administration

Chapter 5. Global Gastric Cancer Market by Treatment Type

Chapter 6. Global Gastric Cancer Market by Disease Type

Chapter 7. Global Gastric Cancer Market by Distribution Channel

Chapter 8. Global Gastric Cancer Market by Drug Class

Chapter 9. Global Gastric Cancer Market by Region

Chapter 10. Company Profiles

胃がんの世界市場規模・シェア・産業動向分析レポート：投与経路別（注射・経口）、治療タイプ別、疾患タイプ別、流通チャネル別、薬剤クラス別、地域別展望・予測、2023～2029年

Global Gastric Cancer Market Size, Share & Industry Trends Analysis Report By Route of Administration (Injectable and Oral), By Treatment Type, By Disease Type, By Distribution Channel, By Drug Class, By Regional Outlook and Forecast, 2023 - 2029

目次

第1章 市場範囲と調査手法

第2章 市場概要

第3章 競合分析- 世界

第4章 世界の胃がん市場：投与経路別

第5章 世界の胃がん市場：治療タイプ別

第6章 世界の胃がん市場：疾患タイプ別

第7章 世界の胃がん市場：流通チャネル別

第8章 世界の胃がん市場：薬剤クラス別

第9章 世界の胃がん市場：地域別

第10章 企業プロファイル

LIST OF TABLES

Scope of the Study

Table of Contents

Chapter 1. Market Scope & Methodology

Chapter 2. Market Overview

Chapter 3. Competition Analysis - Global

Chapter 4. Global Gastric Cancer Market by Route of Administration

Chapter 5. Global Gastric Cancer Market by Treatment Type

Chapter 6. Global Gastric Cancer Market by Disease Type

Chapter 7. Global Gastric Cancer Market by Distribution Channel

Chapter 8. Global Gastric Cancer Market by Drug Class

Chapter 9. Global Gastric Cancer Market by Region

Chapter 10. Company Profiles

第1章市場範囲と調査手法

第2章市場概要

第3章競合分析- 世界

第4章世界の胃がん市場：投与経路別

第5章世界の胃がん市場：治療タイプ別

第6章世界の胃がん市場：疾患タイプ別

第7章世界の胃がん市場：流通チャネル別

第8章世界の胃がん市場：薬剤クラス別

第9章世界の胃がん市場：地域別

第10章企業プロファイル